J1887/Version 7.0 / January 27, 2023 1 TITLE: A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab 
in relapsed/refractory solid tumors with expansions in MSS colorectal cancer 
 Johns Hopkins #: J1887 / IRB00175864 
BMS Protocol #: CA209-8LC 
BAYER Protocol #:  IIR-US-2018-5354 
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]  
 Principal Investigator:  [INVESTIGATOR_307987], MD  
            BMS Supplied Agent : Nivolumab (Opdivo®, BMS-936558) 
 
Bayer Supplied Agent: Copanlisib (BAY 80-6946) 
 
IND Number:   139720       
 IND Sponsor: Nilofer Azad, MD 
 Protocol Version # / Version Date:  Version 1 / May 31, 2018  
 Version 2 / July 10, 2018 
 Version 2.1 / July 13, 2018 
 Version 2.2 / July 18, 2018 
 Version 2.3 / July 24, 2018 
 Version 3.0 / January 10, 2019 
 Version 4.0 / November 14, 2019 
 Version 4.1 / June 17, 2020 
 Version 5.0 / June 25, 2020 Version 5.1 / March 15, 2021 Version 5.2 / March 02, 2022 Version 6.0  /May 11, 2022 Version 7.0 / January 27, 2023 
   

J
1887/Version 7.0 / January 27, 2023 2  
TRIA
L SUMMARY  
 
A
bbreviated Title C
opanlisib and nivolumab in relapsed/refractory solid tumors with 
ex
pansions in MSS colorectal cancer 
T
rial Phase I/II 
C
linical Indication Phase I: Relapsed/refractory MSS solid tumors  
Phase II: MSS colorectal cancer 
T
rial Type Dose Finding / Efficacy and safety 
T
ype of control Single arm (no control) 
R
oute of administration IV 
T
rial Blinding Open Label 
T
reatment Groups  Copanlisib + Nivolumab 
Num
ber of trial participants 51-54 
Estim
ated enrollment period 18 months 
Estim
ated duration of trial 24 months 
 
J
1887/Version 7.0 / January 27, 2023 3 TABLE OF
 CONTENTS 
1. OBJECTIV
ES ..........................................................................................................................9  
1.1 Prima
ry Objectives...................................................................................................9  
1.2 Sec
ondary Objectives...............................................................................................9  
1.3 H
ypotheses ...............................................................................................................9  
1.4 Stud
y Design ..........................................................................................................10  
2. BAC
KGROUND ....................................................................................................................11  
2.1 Copa
nlisib (BAY 80-6946) ....................................................................................11  
2.2 Nivo
lumab..............................................................................................................12  
3. P
ATIENT SELECTION .......................................................................................................16  
3.1 Eligibilit
y Criteria ..................................................................................................16  
3.2 Ex
clusion Criteria ..................................................................................................17  
3.3 I
nclusion of Women and Minorities ......................................................................20  
4. TREA
TMENT PLAN ............................................................................................................20  
4.1 Reg
istration and Enrollment ..................................................................................20  
4.2 Ag
ent Administration.............................................................................................21  
4.3 Do
se Limiting Toxicities .......................................................................................22  
4.4 Do
se Modification and Toxicity Management ......................................................23  
4.5 Du
ration of Therapy and Criteria for Removal from Study Treatment .................36  
4.6 End
 of Treatment (EOT) Visit ...............................................................................37  
4.7 Du
ration of Follow Up ...........................................................................................37  
5. AD
VERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................38 
5.1 De
finitions..............................................................................................................38  
5.2 Rela
tionship ...........................................................................................................40  
5.3 Asse
ssment of Grade..............................................................................................40  
5.4 Ex
pectedness ..........................................................................................................41  
5.5 Ha
ndling of Expedited Safety Reports ..................................................................41  
5.6 Rep
orting................................................................................................................41  
6. P
HARMACEUTICAL INFORMATION ............................................................................44  
6.1 Nivo
lumab..............................................................................................................44  
6.2 Copa
nlisib ..............................................................................................................45  
7. COR
RELATIVE/SPECIAL STUDIES ...............................................................................47  
7.1 Tumo
r Tissue .........................................................................................................47  
7.2 Per
ipheral Blood Mononuclear Cells (PBMCs) ....................................................48  
7.3 Plasma ........
............................................................................................................48  
7.4 Dia
gnostic Tissue Samples ....................................................................................48  
7.5 Planne
d Analyses ...................................................................................................48  
7.6 I
nvestigator Responsibilities for Translational Research ......................................51  
8. STUDY
 SCHEDULE .............................................................................................................52  
8.1 Stud
y Calendar – Phase I .......................................................................................52  
8.2 Stud
y Calendar – Phase II ......................................................................................[ADDRESS_428822] ..........................................................................................58  
9.1 De
finitions..............................................................................................................58  
9.2 Me
thods for Evaluation of Measurable Disease ....................................................58  
J
1887/Version 7.0 / January 27, 2023 4 10. DA
TA REPORTING / REGULATORY REQUIREMENTS ...........................................58  
10.1  Da
ta Management ..................................................................................................59  
10.2  Saf
ety Meetings .....................................................................................................59  
10.3  Monitoring ........
.....................................................................................................60  
11. STATIS
TICAL CONSIDERATIONS .................................................................................60  
11.1  Sample
 Size ............................................................................................................60  
11.2  Statistica
l Analyses ................................................................................................61  
11.3  Saf
ety Analyses ......................................................................................................62  
12. REF
ERENCES .......................................................................................................................64  
AP
PENDIX A: Performance Status Criteria ............................................................................66  
AP
PENDIX B: Contraceptive Guidance and Pregnancy Testing ...........................................67  
AP
PENDIX C: Management Algorithms ..................................................................................69  
AP
PENDIX D: Average Glycemic Index of Common Foods ..................................................77  
AP
PENDIX E: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 
Criteria for Evaluating Response in Solid Tumors .......................................78  
AP
PENDIX F: Serious Adverse Event (SAE) Reporting Form ..............................................81  
 
  
J
1887/Version 7.0 / January 27, [ADDRESS_428823] OF
 ABBREVIATIONS 
 
Abbreviation Definition 
5-HT
3 se
rotonin receptor  
AE adve
rse eve
nt 
AK
T pr
otein kinase B  
A
LT alan
ine aminotransferase (also known as SGPT)  
AN
C absolute
 neutrophil count  
a
PTT ac
tivated partial thromboplastin time  
AST  aspa
rtate aminotransferase (also known as SGOT)  
AU
C are
a under the concentration -time c
urve 
B
AY 80-6946  c
opanlisib  
B
MS B
ristol -M
yers Squibb Company  
B
P blood pr
essure  
B
RAF  v-RAD
 murine sarcoma viral homolog B1  
B
UN blood ur
ea nitrogen  
C cy
cle 
CB
C comple
te blood count  
CCL
2 C-C motif c
hemokine l iga
nd 2 
CD cluster
 of differentiation  (e
.g. CD28 = cluster of differentiation 28)  
CEA  Car
cinoembr
yonic An
tigen  
CF
R code
 of federal regulations  
C
LIA Clinica
l Laboratory Improvement Amendments  
Cmax  ma
ximum serum concentration  
CMV  cy
tomegalovirus  
CNS  ce
ntral nervous system  
CR comple
te re
sponse  
CRC  color
ectal cancer  
CRF  c
ase report form  
CRO  Clinica
l Research Office  
CT compute
d tomography  
CTCAE  c
ommon t e
rminology criteria for adverse events  
CT
LA-4 cy
totoxic T -l
ymphocyte -a
ssociated protein 4  
CV%  (%
 coefficient of variation  
CXC
L9 C-X-C motif c
hemokine ligand 9  
CYP  cy
tochrome P450  
D day 
DCR  dise
ase control rate  
D
ILI dru
g induced liver injury  
D
LT dose
 limiting toxicities  
Do
R dur
ation of response  
DPP4  dipe
ptidyl peptidase 4  
DSMP  da
ta safety monitoring plan  
e
.g. ex
empli gratia , f
or example  
ECG  elec
trocardiogram  
ECO
G Ea
stern Cooperative Oncology Group  
J
1887/Version 7.0 / January 27, 2023 6 Abbre
viation Definition 
EG
FR epi[INVESTIGATOR_345294]
T end of
 treatment  
ESR ex
pedited safety report  
e
tc. e
t cetera , a
nd so forth  
F
DA F
ood and Drug Administration  
F
FPE for
malin -fix
ed pa
raffin -embedde
d 
F
T4 fre
e T4 (or free th
yroxin ) 
g g
ram(s)  
GCP  good c
linical practice  
GF
R glome
rular filtration rate  
GV
P&E  Globa
l Pharmacovigilance and Epi[INVESTIGATOR_623]  
h hour(s) 
H&
E he
matoxylin and eosin  
Hb
A1c he
moglobin A1c  
HB
sAg he
patitis B serum a nti
gen 
HDL  hig
h-de
nsity lipoprotein  
He
pC he
patitis C  
He
pCAb  he
patitis C antibody  
HE
R huma
n epi[INVESTIGATOR_3506]  
H
IV huma
n immunodeficiency virus  
H
LA huma
n leukocyte antigen  
i.e. id e
st, tha
t is 
I
B Inv
estigator ’s br
ochure  
I
C50 ha
lf ma
ximal inhibitory concentration  
I
DO indole
amine -p
yrrole 2,3 -diox
ygenase  
I
F immunof
luorescence  
I
FNγ inte
rferon -g
amma  
I
GF-1R insulin -like g
rowth factor 1 receptor  
I
g immunog
lobulin  
I
gG4 immunog
lobulin G4  
I
gV-t
ype I
g-va
riable –t
ype 
I
HC immunohistoc
hemistry  
IL inte
rleukin (IL -2 
= Interleukin 2, IL -10 =
 interleukin 10, etc)  
I
ND inve
stigational new drug  
I
NR inte
rnational normalized ratio  
I
RB institutional r
eview board  
I
V intra
venous  
J
HU J
ohns Hopkins University  
kg kilog
ram 
KRA
S Kir
sten ras oncogene homolog from the mammalian ras gene family  
L liter
(s) 
L
AG3  ly
mphocyte -a
ctivation gene [ADDRESS_428824]  
J
1887/Version 7.0 / January 27, 2023 7 Abbre
viation Definition 
L
VEF  le
ft ventricular ejection fraction  
mAb  monoc
lonal a
ntibody  
Me
d Hx  me
dical history  
Me
t me
senchymal epi[INVESTIGATOR_345295](s)  
MH
C ma
jor histocompatibility complex  
min minute
(s) 
m
L millil
iter(s)  
mmHg  millimeter
 of mercury  
mmol  millimoles(
s) 
MR
I ma
gnetic resonance imaging  
MSS  micr
osatellite stable  
MTD  ma
ximum tolerated dose  
MU
GA Multi-g
ated a
cquisition s c
an 
mTO
R ma
mmalian target of rapamycin  
N/A not a
pplicable  
NC
I Na
tional Cancer Institute  
NG
S ne
xt generation sequencing  
nM na
nomole, nanomolar  
NRA
S ne
uroblastoma RAS viral  onc
ogene homolog  
NSAI
D non-ster
oidal anti -infla
mmatory drug  
NY
HA Ne
w York Heart Association  
O
I oppor
tunistic Infection  
ORR  ove
rall response rate  
OS ove
rall survival  
OT
C ove
r the counter  
OX-40 OX
40 receptor, also known as CD134, or TNFRSF4  
pA
KT phosph
orylated AKT  
PB
MC pe
ripheral blood mononuclear cells  
PB
S phosph
ate buffered saline  
PCR  pol
ymerase chain reaction  
PD pro
gressive disease  
PD-1 pro
grammed death -1 
PD-L
1 pro
grammed death -ligand 1  
PD-L
2 pro
grammed death -ligand 2  
PDG
FR pla
telet-de
rived growth factor receptor  
PF
S pr
ogression -f
ree survival  
P
I Princ
ipal Investigator  
P
I3K phosp
hatidylinositol 3 -kina
se 
P
IK3CA  phosp
hatidylinositol -4,5-bisphosp
hate 3 -kina
se 
P
IP3 phosp
hatidylinositol -3,4,5 -trispho
sphate  
PJP Pneu
mocystis jirove
ci pneumonia  
PK Phar
macokinetic (s
) 
PKCθ  pr
otein kinase C -the
ta 
PO pe
r os, ora
lly 
J
1887/Version 7.0 / January 27, [ADDRESS_428825] in the 
he
art's electrical cycle  
QT
c c
orrected QT interval  
RB
C re
d blood cell  
REC
IST Re
sponse Evaluation Criteria in Solid Tumors  
RNA  ribonuc
leic acid  
RNA
Seq RNA
 sequencing  
RP2D  re
commended phase II dose  
SAE  se
rious adverse event  
SD stab
le disease  
SG
LT2 sodium/ gluc
ose co -t
ransporter 2  
SGO
T se
rum glutamic -ox
aloacetic transaminase (also known as AST)  
SGPT  se
rum glutamic pyruvic transaminase (also known as ALT)  
SKCCC  Sidney
 Kim me
l Comprehensive Cancer Center  
SOC  stan
dard of care  
SubQ  subc
utaneously  
T1/[ADDRESS_428826] uppe
r limit of normal  
UPCR  urine
 protein:creatinine ratio  
USP Un
ited States Pharmacopeia  
VE
GF va
scular endothelial growth factor  
V
LDL  ve
ry low -de
nsity lipoprotein  
VN
S via
l, needle, and syringe  
v-RAF  viru
s-induc
ed rapi[INVESTIGATOR_345296]
C white b
lood cell  
WOCB
P wome
n of childbearing potential  
WT wildt
ype 
 
  
J
1887/Version 7.0 / January 27, 2023 9 1. OBJECTIV
ES 
 
1.1 Primary Objectives 
 
1. Phase I: To determine the recommended phase II dose (RP2D) of copanlisib with fixed 
dose nivolumab  
2. Phase II/Clinical: To determine 6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab and compare the ORR of patients in Cohort A (MSS colorectal cancer patients with PIK3CA mutations) and Cohort B (MSS colorectal cancer patients with WT PIK3CA) 
 1.2 Secondary Objectives 
 
1. To determine the 6-month disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS) and compare DCR, DoR, PFS, and OS of patients in cohort A and cohort B. 
2. To assess safety and characterize toxicities of the combination of copanlisib and nivolumab 
 
1.[ADDRESS_428827] of copanlisib + nivolumab on markers of immune exhaustion and pro-apoptotic factors in CD8+ effector T cells. 
2. To determine the effect of copanlisib + nivolumab on immune cell subpopulations in the tumor microenvironment, including CD8+ T cells, PD-1/PD-L1 expression on tumor and tumor associated macrophages and monocytes, and MHC 1/[ADDRESS_428828] of copanlisib and nivolumab on local and systemic immune activation pathways and immune suppressive pathways through expression profiling  
4. To explore changes in immune cell subsets and cytokine profiles in the peripheral circulation 
5. To evaluate potential molecular determinants of response, progression, and disease stability using next generation sequencing and other sequencing techniques  
1.4 Hypotheses 
 
1. PI3K inhibition with copanlisib in combination with nivolumab will be tolerable and result in tumor response in tumor types resistant to immune checkpoint therapy  
2. Treatment with copanlisib in advanced solid tumors in combination with nivolumab will result in immunologic changes including:  
- increased numbers of CD8+ cytotoxic T cells 
- decreased T-cell exhaustion 
J1887/Version 7.0 / January 27, 2023 10 - decreased CD4+ T regulatory T cells and myeloid derived suppressor cells  
- changes in gene expression resulting in increased immune activation and 
decreased immune suppression pathways 
- increased activated cytotoxic T-cells, TCR rearrangements, and decreased 
immune suppressive cells 
 
1.5 Study Design  
 
This is a multi-center, open-label, Phase I/II study.  Phase 1 consists of a 3+3 dose de-escalation design to determine the dose of copanlisib for use in combination with nivolumab. 
Approximately 6-18 subjects with solid tumors will be treated in Phase I and will be monitored for dose limiting toxicities (DLTs) through their first cycle of treatment.  Complete information on the definition of DLTs and dose de-escalation rules can be found in Section 4.3 . 
 The Phase II portion of the study will evaluate the safety and clinical activity of copanlisib and 
nivolumab in two cohorts of patients with previously treated metastatic colon cancer. Cohort 
A will enroll patients with PI3K mutation and Cohort B will enroll patients with wildtype PI3K 
status.  Twenty-one patients are targeted for enrollment in each cohort, for an approximate total 
of 42 patients in Phase II. Enrollment in Phase II will be initiated once the recommended phase 
II dose (RP2D) has been determined in Phase I.  
 For all patients, the study will consist of a screening period, a treatment period, and a follow-up period.  Screening evaluations will be done within 28 days prior to the start of study treatment.  
 
Each treatment cycle is 28 days.  Patients in both Phase I and Phase II will receive nivolumab 
on Day 1 of each cycle (every 4 weeks) and copanlisib on either Day 1, Day 8, and Day 15 of each cycle (3 week on, one week off) or on Day 1 and 15 of each cycle (every 2 weeks), depending on the dose level and RP2D.  Complete information on study drug administration, schedule, and dosing can be found in Section 4.2. 
 Phase II enrollment will be carried out in [ADDRESS_428829] 12 patients, the study will be terminated for futility. Otherwise, 9 additional patients will be accrued for a 
total of 21 treated subjects. If [ADDRESS_428830] withdrawal, or study closure. Complete criteria for removal from treatment are found in Section 4.5 .   
 Subjects will undergo end-of-treatment (EOT) evaluations at the time it is determined they will 

J1887/Version 7.0 / January 27, [ADDRESS_428831].   
 2. BACKGROUND  
 
2.1 Copanlisib (BAY 80-6946) 
 
 

J1887/Version 7.0 / January 27, [ADDRESS_428832] common drug-
related adverse events (>20% of patients) included hyperglycemia, nausea, and hypertension. Other toxicities occurring with copanlisib administration included serious infections (19%), grade 4 neutropenia (12%), non-infectious pneumonitis (5%), and transient serious hypertension (1%) or hyperglycemia (1%).     For additional preclinical and clinical trial information, refer to the Investigator’s Brochure. 
 
2.2 Nivolumab 
 Nivolumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).  Based on preclinical in vitro data, nivolumab has high affinity and potent receptor blocking activity for PD-1.  Nivolumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies.  OPDIVO™  (nivolumab) is approved for the treatment of several types of cancer 
because of its mechanism of action to bind the PD-[ADDRESS_428833] hijacked by [CONTACT_44857].  The normal function of PD-1, expressed on the cell surface of activated T-cells under healthy conditions, is to down-modulate unwanted or excessive immune responses, including autoimmune reactions. PD-1 (encoded by [CONTACT_13228]1 ) is an 
immunoglobulin (Ig) superfamily member related to cluster of differentiation 28 (CD28) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) that has been shown to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2).
1, 2  
 The structure of murine PD-1 has been resolved.
3  PD-1 and its family members are type I 
transmembrane glycoproteins containing an Ig-variable–type (IgV-type) domain responsible for ligand binding and a cytoplasmic tail responsible for the binding of signaling molecules.  The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling motifs, an 

J1887/Version 7.0 / January 27, 2023 13 immunoreceptor tyrosine-based inhibition motif, and an immunoreceptor tyrosine-based 
switch motif.  Following T-cell stimulation, PD-1 recruits the tyrosine phosphatases, SHP-1 and SHP-2, to the immunoreceptor tyrosine-based switch motif within its cytoplasmic tail, leading to the dephosphorylation of effector molecules such as CD3 zeta (CD3ζ), protein kinase C-theta (PKCθ), and zeta-chain-associated protein kinase (ZAP70), which are involved 
in the CD3 T-cell signaling cascade.
2, 4-[ADDRESS_428834] from that of CTLA-4, because both molecules 
regulate an overlappi[INVESTIGATOR_77971].7, 8  
 The PK of single-agent nivolumab was studied in patients over a dose range of 0.1 to 20 mg/kg administered as a single dose or as multiple doses every 2 or 3 weeks. Nivolumab clearance decreases over time, with a mean maximal reduction (% coefficient of variation [CV%]) from baseline values of approximately 24.5% (47.6%) resulting in a geometric mean steady state clearance (CLss) (CV%) of 8.2 mL/h (53.9%); the decrease in CLss is not considered clinically relevant. The geometric mean volume of distribution at steady state (Vss) (CV%) is 6.8 L 
(27.3%), and geometric mean elimination half-life (t1/2) is 25 days (77.5%). Steady-state 
concentrations of nivolumab were reached by [CONTACT_3450] 12 weeks when administered at 
3 mg/kg every 2 weeks, and systemic accumulation was approximately 3.7-fold. The exposure to nivolumab increased dose proportionally over the dose range of 0.1 to 10 mg/kg administered every 2 weeks.  Refer to the Investigator’s Brochure for Preclinical and Clinical data. 
 
Recent trials of immune checkpoint blockade have shown striking clinical activity against a range of tumors. However, response to immune checkpoint blockade targeting CTLA4 and PD-1 is still limited, with only a subset of solid tumor patients showing clinical response
9-13. 
Loss of PTEN promotes resistance to T cell–mediated immunotherapy   PTEN is a negative regulator of PI3K, therefore loss of PTEN phenocopi[INVESTIGATOR_345297]3K. When PTEN is lost, the PI3 Kinase pathway is thought to rely on the   isoform of PI3K 
for signaling
14. Melanoma patients with PTEN loss were enriched in nonresponders to anti-
PD-1 and their tumors had fewer infiltrating CD8+ T cells. In a mouse Braf-/- Pten-/-  mutant 
model of induced melanoma treated with adoptive transfer of antigen specific T cells and a tumor antigen vaccine, synergistic response was seen with [COMPANY_004]2636771, a PI3K   inhibitor, 
and anti-PD-1
15. 
 
Loss of PTEN is associated with resistance to Anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma   A single patient experience was described to address a mechanism of resistance to PD-1. A patient with metastatic uterine leiomyosarcoma had up front resection followed by [CONTACT_294819] 

J1887/Version 7.0 / January 27, [ADDRESS_428835] to whole genome and RNA sequencing, which was compared to sequencing performed at diagnosis. The only genomic difference was biallelic loss of PTEN , leading the authors to hypothesize that this genomic 
difference may underlie differential sensitivity to PD-1 blockade. Decreased inflammation was 
shown in the PTEN null progressive lesion by [CONTACT_345317].
16  
 
PI3K inhibition reduces mammary tumor growth and facilitates anti-tumor immunity and anti-PD1 responses   Response to PI3K inhibition and PD-1 blockade was studied in orthotopic implants of mammary tumor cell lines 4T1 and PyMT. PI3K inhibition was achieved by [CONTACT_345318]-PI3K inhibitor BKM120. BKM120 increased sensitivity to anti-PD-1.  The proposed mechanism in this study was recruitment of a myeloid population dependent on PI3Kɣ.
17  
                         
PIK3CA H1047R confers resistance to checkpoint blockade   
 
An experimental system was developed to identify genes used by [CONTACT_345319], gain-of-function genetic screens in mouse transplantable models of cancer
18. Murine tumor cells (MC38 colon carcinoma or B16 melanoma) were transduced with 
a pool of vectors encoding mutant alleles as open reading frames (ORFs) corresponding to a 

 
PI3K Inhibition with copanlisib is synergistic with anti-PD-1 in the A20 mouse lymphoma 
model 

J1887/Version 7.0 / January 27, [ADDRESS_428836] apply: 
 
1. Be willing and able to provide written informed consent for the trial 
 
2. Be at least [ADDRESS_428837] histologically confirmed metastatic or unresectable: 
a. Mismatch-repair proficient (MSS) solid tumor (for phase I dose de-escalation) 
OR 
b. Mismatch-repair proficient (MSS) colorectal cancer with known PI3K-mutation status (for expansion cohorts). NGS and PCR based testing by a CLIA 
certified lab will be used to determine PI3K status per Section 7.5.1 . 
4. In terms of prior therapi[INVESTIGATOR_014]: 
a. For phase I dose de-escalation: have received all curative treatment options AND at least 2 lines of systemic therapy in the metastatic setting 
b. For MSS colorectal cancer cohorts in phase II expansion: have received at least [ADDRESS_428838] therapy including a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen.  KRAS/NRAS/BRAF wild type patients must have received or refused anti-EGFR therapy. 
 
5. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.  
6. Have biopsiable disease.  If biopsy is attempted and unsuccessful (the patient undergoes 
an invasive procedure), the patient may still be treated.   
7. Have a performance status of 0 or 1 on the ECOG Performance Scale at study entry (See Appendix A).   
8. Have a life expectancy of 3 months  
9. Demonstrate adequate baseline laboratory values as defined below; all screening labs should be performed within 21 days of treatment initiation. 
 

J
1887/Version 7.0 / January 27, 2023 17 Syste
m – L
ab L
aboratory Value 
He
matological  
A
bsolute neutrophil count (ANC)  ≥ 
1500/µL 
P
latelets  ≥ 
75 00
0/µL  
He
moglobin  ≥ 
8.0 g/dL or ≥5.6 mmol/La 
Renal  
Serum
 Creatinine  ≤ 1.5 × ULN or 
Glo
meru
lar filtration rate (GFR) ≥4
0 mL/min/1.73  
Urin
e protein:creatinine ration (UPCR) < 3.5 on a random urine sample 
Hepat
ic/pancreatic  
T
otal bilirubin ≤ 1.5 ×ULN (< [ADDRESS_428839] for patients with Gilbert’s 
syndrome) 
AST
 (SGOT) and ALT (SGPT)  ≤ 
3 × UL
N  
L
ipase  < [ADDRESS_428840]  
E
ndocrine  
HbA
1c ≤ 
7%  
Glu
cose < 1
60 mg/dL (fasting) or < 200 mg/dL (non -f
asting)  
Coa
gulation  
Intern
ational normalized ratio (INR) and 
par
tial thromboplastin time (PTT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of 
an
ticoagulants  
Cardiac 
L
eft ventricular ejection fraction (LVEF)  ≥ 
50% 
a C
riteria must be met without erythropoietin dependency and without packed red blood cell 
(pRBC) transfusion within last 1 week.  
b C
reatinine clearance (CrCl) should be calculated per institutional standard. 
 
10. Ma
le subjects must agree to use a contraception as detailed in Appendix B  of this 
protocol during the treatment period and for at least [ADDRESS_428841] not be pregnant (negative urine or serum test within [ADDRESS_428842] dose of study drug) or breastfeeding, and at least one of the following conditions must apply: 
a. Not a woman of childbearing potential (WOCBP) as defined in Appendix B  or 
b. A 
WOCBP who agrees to follow the contraceptive guidance in Appendix B  
during the treatment period and for at least [ADDRESS_428843] dose of study drug. 
 
3.2 Exclusion Criteria 
 
Subjects are excluded from the study if any of the following criteria apply: 
 
1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with 
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137).  
2. Prior therapy with a PI3K inhibitor 
J
1887/Version 7.0 / January 27, [ADDRESS_428844] recovered from all AEs 
due to previous interventions to ≤Grade 1 or baseline. Participants with ≤ grade 2 neuropathy, anemia, and/or alopecia may be eligible. 
 
4. Has received prior radiotherapy within [ADDRESS_428845] recovered from all radiation-related toxicities to ≤Grade [ADDRESS_428846] had radiation pneumonitis.  A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. Participants with ≤ grade 2 neuropathy, anemia, and/or alopecia may be eligible.  
5. Is currently participating in or has participated in a study of an investigational agent or investigational device within [ADDRESS_428847] dose of study treatment. (i.e. must be [ADDRESS_428848] dose of the previous investigational agent).  
6. Has received a live vaccine within [ADDRESS_428849] dose of study drug.  Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. 
 
7. Has a known additional malignancy that is progressing or requires active treatment.  Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy. 
 
8. Has known CNS metastases and/or carcinomatous meningitis.   
9. Has symptomatic ascites or has required a paracentesis in the last 12 weeks 
10. Has known hypersensitivity to nivolumab, copanlisib, or any ingredients in the 
formulation of these study drugs. 
 11. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy 
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within [ADDRESS_428850] 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy are exceptions. Intermittent use of bronchodilators or local steroid injections are not excluded. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a form of systemic treatment. Autoimmune diagnoses not listed must be approved by [CONTACT_407]. 
J
1887/Version 7.0 / January 27, 2023 19 13. Ha
s a history of (non-infectious) pneumonitis that required steroids or has current 
pneumonitis. 
14. Has an active infection requiring systemic therapy. 
15. Has a known history of Human Immunodeficiency Virus (HIV) infection.   
16. Has a known history of Hepatitis B (HBsAg reactive) or active Hepatitis C virus 
infection (HepCAb followed by [CONTACT_345320]).  
17. CMV PCR positive 
18. Has a history or concurrent condition of interstitial lung disease or severely impaired lung function  (as judged by [CONTACT_093]) 
19. Has Type I diabetes or Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin. 
20. Uncontrolled cardiovascular disease 
a. Congestive heart failure > [LOCATION_001] Heart Association (NYHA) class 2 
b. Unstable angina (symptoms at rest), new-onset angina (within the last 3 months).  
c. Myocardial infarction less than [ADDRESS_428851] drug  
d. Uncontrolled arterial hypertension despi[INVESTIGATOR_3062] 
 21. Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted)  
22. Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment. Examples of inhibitors of CYP3A4: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir.  Examples of inducers of CYP3A: rifampin, phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, St. John’s Wort.    See Table [ADDRESS_428852]. 
 
23. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months before the start of study medication 
 24. Non-healing wound, ulcer, or fracture 
25. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication  
26. Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment 
27. Seizure disorder requiring anti-seizure medication 
28. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 
J1887/Version 7.0 / January 27, [ADDRESS_428853]’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_80021].   
30. Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the study, starting with the screening visit through [ADDRESS_428854] will be supplied to each participating site. If a patient does not receive protocol therapy following registration, the patient’s registration on the study may be canceled.  The Study Coordinator should be notified of cancellations as soon as possible.  
de-identified documents should be completed and sent to 
 Registration Form 
 Signed patient consent form with printed patient name [CONTACT_345346] 
 Eligibility Checklist 
 Participating Sites: copy of required screening tests, scans, and notes used to verify eligibility 
 Coordinating Center (Johns Hopkins University): required screening tests, scans, and 
notes will be verified for eligibility through internal electronic clinic system. 
 
The Research Nurse or Lead Study Coordinator at the participating site will then e-mail the 
Protocol Chair to verify eligibility. To complete the registration process, the Lead Study Coordinator will: 
 Assign a patient study number 
 Register the patient on the study 
 Fax or e-mail the patient study number to the participating site 
 Call or e-mail the research nurse or data manager at the participating site and verbally confirm registration. 

J1887/Version 7.0 / January 27, 2023 21  
4.2 Agent Administration 
 
There will be two phases in this study: A Phase I dose-finding stage followed by a Phase II 
expansion.  
 
Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at the doses and 
days shown in Table 1  and Table 2  below. Subjects should be observed for a minimum of 30 
minutes after administration of Copanlisib prior to administration of nivolumab.  Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.  The Pharmacy Manual contains specific instructions for the preparation and administration of these study drugs.  
 
Study treatment should be administered after all procedures/assessments have been completed 
for that visit as detailed on the Study Calendar ( Section 8 ).  Study treatment may be 
administered up to 3 days before or after the scheduled Day 1 of each cycle, up to 1 day after the scheduled Day 8, or up to 3 days after Day 15 of each cycle due to administrative reasons as long as there is a minimum of 7 days between copanlisib infusions.  All trial treatments will be administered on an outpatient basis.   Phase I – Dose De-Escalation 
 Phase I will use a standard 3+3 design.  The initial dose being tested is the recommended phase 2 dose of both study drugs as single agents, so the doses of copanlisib and nivolumab will not escalate higher than dose level 1.  However, if the recommended phase II dose (RP2D) is exceeded in dose level 1, the dose of copanlisib will de-escalate as indicated below in Table 1.  A maximum of 18 eligible subjects will be enrolled into this phase.  All patients enrolled at each dose level will be evaluated for dose limiting toxicities (DLTs) during the first 28 day cycle for the purpose of determining the RP2D when given concurrently with nivolumab. DLTs and dose de-escalation rules are defined in Section 4.3  and Table 3 , respectively. 
 Table 1 – Phase I Dose Levels and Regimen  (listed in order of administration) 

J1887/Version 7.0 / January 27, 2023 22  
Phase II – Expansion Cohorts 
 
Phase II will enroll patients with mismatch-repair proficient colorectal cancer with known PI3K-mutation status.  21 patients will be enrolled into Cohort A (PIK3CA mutation) and 21 
patients will be enrolled into Cohort B (PIK3CA WT).  Both cohorts will receive the same 
treatment regimen. The dose of copanlisib given in Phase II will be the RP2D determined 
during Phase I of this study.   
 
Table 2 - Phase II Regimen (listed in order of administration) 
 
4.3 Dose Limiting Toxicities 
 
Dose limiting toxicities (DLTs) are defined as any AE occurring within the first cycle of treatment that is temporally related to study drug administration, which is not due to the subject’s underlying malignancy, for which there is no clear evidence for an alternative etiology, and that meets one of the following NCI CTCAE criteria: 
 
Hematologic Toxicities  
- Grade 4 anemia  
- Grade ≥ 3 neutropenia lasting ≥ 14 days  
- Grade ≥ 3 febrile neutropenia 
- Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia with clinically significant bleeding  
 
Other Toxicities  
- Treatment-related ≥ grade 4 AEs, except transient hyperglycemia  
- Grade ≥ 3 Pneumonitis or recurrent Grade 2 pneumonitis 
- Grade ≥ 3 Nephritis 
- Grade ≥ [ADDRESS_428855], ALT 
- Grade ≥ 2 eye pain or reduction of visual acuity that does not respond to topi[INVESTIGATOR_139] ≤ grade 1 severity within 2 weeks of starting therapy, or requires systemic therapy 
- Any other Grade ≥ 3 toxicities except 
- Grade 3 nausea, vomiting, or diarrhea that resolves to Grade ≤ 1 within 7 days, with or without appropriate supportive therapy  
- Grade 3 rash that resolves to Grade ≤ 2 within 7 days  
- Grade 3 fatigue that resolves to ≤ Grade 2 within 14 days  

J
1887/Version 7.0 / January 27, 2023 23 - Gr
ade 3 transient hypertension and transient hyperglycemia 
- Grade ≥ 3 laboratory abnormalities that, in the judgment of the investigator, 
are not clinically significant  
- Asymptomatic amylase/lipase elevation 
 
Unexpected Grade 3 or greater laboratory abnormalities should be repeated within 24-72 hours 
if clinically indicated and monitored as necessary to determine if event meets toxicity criteria. 
 
Table 3 – Dose De-Escalation Rules 
Number of Patients 
with DLT at a 
Given Dose Level Dose De-Escalation Decision Rule  
(dose levels found in Table 1) 
0-1 out of 3 Enter
 3 more patients at this dose level 
 
 If ≤ 1 of 6 subjects in this cohort experience a DLT, this is 
the recommended phase II dose (RP2D) 
 If ≥ 2 of 6 patients in this cohort experience a DLT, this dose 
level exceeded the RP2D. 3 patients will be entered at the 
next lower dose level. 
≥ 2 ou
t of 3 This dose level exceeded the RP2D. 3 additional patients will be 
entered at the next lower dose level. 
 
4.4 Do
se Modification and Toxicity Management 
 
4.4.1 Dosing Delays and Modifications 
 
Study treatments are scheduled on a 3 weeks on, 1 week off schedule.   
 
 Start of a treatment cycle (Day 1) will be delayed for toxicity until retreatment criteria are met. The Principal Investigator [INVESTIGATOR_345298] 1 week. If delays are required due to toxicity related to one study drug but not the other, all study treatment will be delayed.   
 
 If the day 8 or day 15 dose of copanlisib needs to be delayed longer than 2 days due to toxicity, the dose(s) should be skipped and the remainder of the cycle continued once retreatment criteria are met.  The intention here is to keep the length of each cycle to [ADDRESS_428856] dose level of copanlisib and meets criteria for further decrease, study treatment will be discontinued permanently. There will be no dose re-escalation for DLTs.  Dose re-escalation may be allowed for non-DLTs at the PI’s discretion after patient has fully recovered from the toxicity and in the absence of any other 
J
1887/Version 7.0 / January 27, 2023 24 a
dverse events that require dose-reduction, with the exception of non-infectious 
pneumonitis. 
 Dosing of study therapy will be delayed for the following criteria (or Table 4 criteria):  
 AST/ALT >3 × ULN 
 Total bilirubin > 1.[ADDRESS_428857]  (> 2.0 × ULN for subjects with Gilbert’s syndrome) 
 Creatinine > 1.5 × ULN or GFR < 40 mL/min/1.73 m
2 
 He
moglobin < 8 g/dL 
 ANC < 1250/uL (day 1) and < 1000 (days 8 and 15) – hold both study drugs 
 Platelets < 75 × 103/u
L 
 Fasting Glucose (Cycle 1 Day 1) >125 mg/dL (non-diabetic patients) or ≥160 mg/dL (diabetic patients) 
 Fasting glucose (all other days) > 160 mg/dL 
 CMV PCR > 500 IU/mL (tested each cycle for cycles 1-6, and every 3 months thereafter) 
 Any
 Grade ≥  2 non-skin, nivolumab-related adverse event, with the following 
exceptions: 
 Grade 2 fatigue 
 Grade 2 lab abnormalities 
 Grade 2 hypothyroidism or thyroiditis 
 Any
 Grade  ≥  3 skin nivolumab-related AE 
 Any
 Grade  ≥  3 nivolumab-related laboratory abnormality with the following 
exceptions: 
 Grade 3 lymphopenia 
 Any Grade ≥ 3 drug-related amylase or lipase abnormality that is not associated with symptoms or clinical manifestations of pancreatitis 
 Isolated grade 3 or 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with supplementation/appropriate management 
 Any
 AE, laboratory abnormality, or inter-current illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
J
1887/Version 7.0 / January 27, 2023 25 Table
 4 - Dose modificat
ion and toxicity management guidelines for AEs associated with copanlisib  
Drug-rela
ted 
AEs Grade
 (CTCAE 
v5.0
) or 
m
easurement Act
ion taken to 
study
 drugs Ret
reatment 
Do
se Level AE 
management M
onitor and follow-up 
H
yperglycemia Grade 1: 
Asymptomatic 
glucose above 
baseline with no 
medical 
intervention Withhold until 
pre-infusion 
glucose is <160 
mg/dL (fasting)  No change in dose  Hydration as appropriate 
 May follow without glucose-
lowering tx if repeated glucose 
value is decreasing and hydration 
status is normal  Repeat glucose testing  
 Endocrinologist consult recommended  
 Cons
ider prophylaxis with oral 
glucose lowering tx for next dose:  
 Recommended (preferred order): SGLT2 inhibitor,  DPP4 inhibitor, 
metformin, and/or thiazolidinedione 
 Not recommended:  Use of 
sulphonylurea/ metaglinides, insulin secretagogues to manage increased 
glu
cose levels post drug infusions  
S
ymptomatic or 
persisting glucose 
>250mg/dL 1 W
ithhold until 
pre-infusion 
glucose is <160 
mg/dL (fasting)  No change in dose  Hydration as clinically 
appropriate 
 Glucose-lowering medication 
should be given: 
 Recommended (preferred 
order): SGLT2 inhibitor,  DPP4 
inhibitor, metformin, and/or thiazolidinedione 
 Not recommended:  Use of 
sulphonylurea/ metaglinides, 
insulin secretagogues to manage 
increased glucose levels post 
drug infusions  Assess hydration status 
 Repeat glucose testing 
 Consult with endocrinologist 
 Consider prophylaxis with oral 
glucose lowering tx for next dose: 
 Recommended (preferred order): 
SGLT2 inhibitor,  DPP4 inhibitor, 
metformin, and/or thiazolidinedione 
 Not recommended:  Use of 
sulphonylurea/ metaglinides, insulin 
secretagogues to manage increased 
glucose levels post drug infusions P
ersistent glucose  
>5
00 mg/dL1  W
ithhold until 
pre-infusion 
glucose is <160 
mg/dL (fasting)  Decrease by [CONTACT_345321] [ADDRESS_428858].  
Ma
x glucose  
>200mg/dL on subsequent days 
after infusion N/A N/A  Treatment with glucose-lowering 
medication per local standards 
 Recommended (preferred 
order): SGLT2 inhibitor,  DPP4 
inhibitor, metformin, and/or 
thiazolidinedione 
 Not recommended:  Use of 
sulphonylurea/ metaglinides, insulin secretagogues to manage 
increased glucose levels post 
d
rug infusions   End
ocrinologist consult 
recommended 
J
1887/Version 7.0 / January 27, 2023 26 Table
 4 - Dose modificat
ion and toxicity management guidelines for AEs associated with copanlisib  
Drug-rela
ted 
AEs Grade
 (CTCAE 
v5.0
) or 
m
easurement Act
ion taken to 
study
 drugs Ret
reatment 
Do
se Level AE 
management M
onitor and follow-up 
A
rterial 
Hypertension Pre-dose BP 
>150/90 mmHg Withhold2  No
 change in dose  Consider BP-lowering medication  Measure BP every 5-10 minutes (no 
more than 4 measurements) until 
acc
eptable for treatment .   
B
P during 
infusion  
>160/100 mmHg Interrupt if having 
symptoms 
attributable to 
h
ypertension2  Next d
ose reduced by [CONTACT_345322]’s 
discretion  Initiate BP lowering medication 
according to standard of care  Monitor BP as clinically indicated 
until <150/90. 
P
ost-dose BP 
>160/100 mmHg3 N/
A 
 Monitor BP as clinically indicated. 
Gr
ade 4 Permanently 
discontinue N/A 
No
n-infectious 
Pneumonitis Grade 2 Withhold  Decrease by [CONTACT_345323] 3 or 4  
or recurrent 
Gr
ade 2  P
ermanently 
discontinue N/A 
Inf
ections Gr
ade 3 or higher  W
ithhold  N/
A   
Sus
pected PJP 
infection of any 
grad
e W
ithhold.  
Resume once 
in
fection resolves  N/
A If confirmed PJP, treat infection 
until resolution Treat with concomitant PJP prophylaxis after resolution/ restarting of copanlisib 
Der
matologic / 
Cutaneous AEs Grade [ADDRESS_428859]: no
 dose change 
2nd-3rd: d
ecrease by [CONTACT_23615] 
4th: d
iscontinue  
  
Gr
ade [ADDRESS_428860]-2nd: d
ecrease by [CONTACT_23615] 
3rd: d
iscontinue  
Gr
ade 4 Permanently 
d
iscontinue  N/
A 
He
matological 
toxicitiy4  Gr
ade 2 
neutropenia or 
thrombocytopenia on day 1 of each 
c
ycle W
ithhold No change in dose   
J
1887/Version 7.0 / January 27, 2023 27 Table
 4 - Dose modificat
ion and toxicity management guidelines for AEs associated with copanlisib  
Drug-rela
ted 
AEs Grade
 (CTCAE 
v5.0
) or 
m
easurement Act
ion taken to 
study
 drugs Ret
reatment 
Do
se Level AE 
management M
onitor and follow-up 
Gr
ade ≥ 3  Withhold Decrease by [CONTACT_345324]’s discretion   T
reatment with transfusion or 
growth factors allowed at PI’s 
d
iscretion  
Other
 non-
hematological toxicities Grade [ADDRESS_428861]: no
 dose change  
2nd-3rd: d
ecrease by [CONTACT_23615] 
4th: d
iscontinue     Gr
ade 4 or any 
toxicity requiring delay for >21 
d
ays P
ermanently 
discontinue N/A 
[ADDRESS_428862]  
2. Infusion may proceed/resume on scheduled day if BP recovers to <150/90 mmHg for 2 consecutive measurements and symptoms (if present) resolve.  
3. Despi[INVESTIGATOR_345299] 
4. Thrombocytopenia, neutropenia, febrile neutropenia, anemia, INR or PTT with bleeding 
 
Genera
l instructions: 
 For situations where drug is withheld due to a copanlisib-related AE, treatment can be resumed after AE has been reduced to Grade [ADDRESS_428863] dose.  
 If patient is already on lowest dose level and meets criteria for further decrease, study drug will be discontinued permanently. 
 Dose re-escalation may be allowed at the PI’s discretion after patient has fully recovered from the toxicity and in the absence of any other adverse events 
that require dose-reduction, with the exception of non-infectious pneumonitis. 
 
A
bbreviations:  S
GLT2 = Sodium/Glucose co -tra
nsporter 2; DPP4 = Dipeptidyl peptidase 4 ; PJ
P= pneumocystis jiroveci pneumonia  
 
 
J
1887/Version 7.0 / January 27, 2023 28 I
n order to standardize the management of AEs for all subjects, treatment management 
algorithms are included in Appendix C . Additional AE treatment management algorithms 
included in the nivolumab IB might be considered for individual cases. 
 Subjects who require a delay in study treatment should be re-evaluated weekly or more frequently if clinically indicated and resume dosing when re-treatment criteria are met. 
 
Subjects may resume treatment with study drug when the nivolumab-related AE(s) resolve to grade ≤1 or baseline value, with the following exceptions:  
 Subjects may resume treatment in the presence of grade 2 fatigue. 
 Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in the presence of Grade 2 skin adverse event 
 Treatment-related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline before treatment is resumed. 
 Treatment-related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment, which include grade [ADDRESS_428864] dose or corticosteroids cannot be reduced to ≤ 10 mg prednisone or equivalent per day within 12 weeks. 
 
4.4.2 Toxicity-Related Treatment Discontinuation  
 
In addition to the discontinuation criteria listed in Table 4  above, permanent 
discontinuation of study treatment should be considered for any severe or life-threatening treatment-related AEs, including, but not limited to, any of the following (the IND Sponsor and BMS must be notified in the event of these AEs): 
 Any grade 2 treatment-related uveitis, eye pain, or blurred vision that does not 
respond to topi[INVESTIGATOR_20308] 1 severity within 2 weeks 
of starting therapy OR requires systemic treatment 
 Any grade 3 non-skin, drug-related AE lasting > 7 days, with the following exceptions: 
o Grade 3 treatment-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, myocarditis, neurologic toxicity, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation 
o Grade 3 treatment-related endocrinopathies adequately controlled with only physiologic hormone replacement do not require discontinuation. Treatment should be discontinued for grade 3 adrenal insufficiency. 
o Grade 3 treatment-related laboratory abnormalities do not require treatment discontinuation except: 
 Grade 3 treatment-related thrombocytopenia > 7 days or that is associated 
with bleeding requires discontinuation 
J
1887/Version 7.0 / January 27, 2023 29  Any
 treatment-related liver function test (LFT) abnormality that meets the 
following criteria require discontinuation: 
 Tota
l bilirubin > 5 × ULN 
 Conc
urrent AST or ALT > 3 × ULN and total bilirubin > 2 × ULN 
 
 Any grade 4 treatment-related AE or laboratory abnormality, except for the 
following events which do not require discontinuation: 
o Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations, or radiographic signs of pancreatitis.  
o Isolated grade 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset. 
o Grade 4 lymphopenia and leukopenia. 
o Grade 4 treatment-related endocrinopathy adverse events, such as ACTH deficiency, hyper- or hypothyroidism, or glucose intolerance, which resolve or are adequately controlled with physiologic hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, respectively, may not require discontinuation after discussion with and approval from the IND Sponsor. 
 
4.4.[ADDRESS_428865] 30 minutes after the end of the infusion, in an area containing resuscitation equipment and medications necessary for advanced life support and cardiopulmonary resuscitation.  Toxicity management guidelines on drug-related infusion reactions are provided in Table 
5. 
   
 
      
J
1887/Version 7.0 / January 27, 2023 30 Table 5 - Infusion Re
action Dose modification and Treatment Guidelines 
N
CI CTCAE Grade  T
reatment  P
remedication at  
Subsequent Dosing  
G
rade 1 
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  Monitor vit
al signs as medically indicated 
until the participant is deemed medically 
stable in the opi[INVESTIGATOR_871].  P
articipant may be premedicated at 
least 30 minutes before infusion of nivolumab with:  
Diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine)  
and/or  Acetaminophen 325-1000 mg PO 
(o
r equivalent dose of analgesic)  
G
rade 2 
Moderate reaction; requires 
therapy or infusion 
interruption but responds 
promptly to symptomatic treatment (e.g., 
antihistamines, NSAIDs, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤[ADDRESS_428866] 
with diphenhydramine 50 mg IV (or 
equivalent) and/or acetaminophen 325-
1000 mg; monitor subject until resolution 
of symptoms.  Corticosteroid and/or bronchodilator therapy may also be 
administered as appropriate.  
If symptoms resolve within 1 hour of 
stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusion 
rate. Otherwise dosing will be held until 
symptoms resolve and the participant 
should be premedicated for the next 
scheduled dose.   
If symptoms recur, then no further 
nivolumab will be administered at that 
v
isit.   P
articipant may be premedicated at 
least 30 minutes before infusion of 
nivolumab with: 
Diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine). 
and/or 
Acetaminophen 325-1000 mg PO 
(or equivalent dose of analgesic). 
If necessary, corticosteroids (up to 
25 mg of SoluCortef or equivalent) 
may be used. 
 
G
rades 3 or 4 
Grade 3: Severe reaction; 
prolonged (i.e., not rapi[INVESTIGATOR_38194]/or brief interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; 
hospi[INVESTIGATOR_345300] 4: Life-threatening; 
urgent intervention 
indicated
 Stop Infus
ion. 
Begin IV normal saline and treat as follows: 
Investigators should follow institutional 
guidelines for the treatment of anaphylaxis.  
 
R
ecommended bronchodilators, 
epi[INVESTIGATOR_238] 0.2-1 mg of a 1:1000 solution 
for SubQ or a 0.1-0.25 mg of a 1:10,000 
solution injected slowly IV (or equivalent), 
as needed. 
Subject should be monitored until 
symptoms resolve and the investigator is 
comfortable that the symptoms will not 
recur.   
Participant is permanently discontinued 
from further study drug treatment.  No su
bsequent dosing  
A
ppropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of 
dru
g administration.  
 
  
J
1887/Version 7.0 / January 27, 2023 31 4.4.4 Additional 
Toxicity Monitoring and Prevention 
 
[IP_ADDRESS]  Glucose and Diet Monitoring 
Table 6 - Fasting requirements and pre-dose glucose levels 
Period  Fastin
g ≥ [ADDRESS_428867] glucose 
measurement  Pre-dose 
glucose levels  
Da
y 1 of Cycle 1  Y
es  <125
 mg/dL (non-diabetic patients) 
<160 mg/dL (diabetic patients)   
Subseq
uent infusions 
after Cycle 1 Day 1  Y
es <160
 mg/dL (fasting) 
<200 mg/dL (non-fasting)  
 
F
asting refers to a ≥ [ADDRESS_428868] on the PI3K α-isoform, which is implicated in insulin metabolism, copanlisib infusions could be associated with a temporary increase in blood glucose. Addition of a meal in close proximity to copanlisib infusion may exacerbate glucose increase.  
On infusion days a low calorie or low carbohydrate diet is recommended. It is 
recommended that timing and content of caloric intake as well as additional glucose testing (if clinically indicated) on infusion days is monitored by [CONTACT_345325]. Consultation with a diabetologist or endocrinologist is advised . 
All glucose measurements, oral glucose lowering medication and/or insulin administration, if applicable, fasting/non-fasting status, and meal intake timing on infusion days will be collected as part of the clinical source documentation.   
 
Glucose monitoring on study 
 Ma
nagement of hyperglycemia and dose delay parameters are outlined in Table 4  
 The following assessments should be performed on Day 1, 8, and 15 of each cycle before receiving copanlisib unless otherwise specified: 
 Patients should be fasting for at least 12 hours prior to the pre-dose glucose measurement.  For details on fasting requirements and glucose measurement during C1D1 please refer to Table 6  
 Blood glucose will be measured at 0 hours (pre-dose) and 1 hour after completion 
of copanlisib (+/- 15min) infusion. If [ADDRESS_428869]-infusion blood glucose is ≥35 
mg/dL higher than pre-dose level, recheck in another hour ([ADDRESS_428870]-infusion) to ensure decline in blood glucose. Additional measurements to be performed as clinically indicated.  
J
1887/Version 7.0 / January 27, 2023 32 NO
TE: If patient needs to take a low glycemic meal, then glucose test should be 
taken prior to meal intake. 
 Prior to first cycle, patients should be educated on the signs and symptoms of 
hyperglycemia, such as frequent urination, increased thirst, blurred vision, headaches and difficulty concentrating and must report these to the investigator or their physician immediately.  
 
[IP_ADDRESS]  Blood pressure measurement on treatment days 
 Blood pressure will be measured every 5 – 10 minutes prior to each copanlisib dose (no more than 4 measurements) until there are two consecutive results < 150/90 mmHg. If blood pressure is ≥ 150/[ADDRESS_428871] for 5-10 minutes before next blood pressure is recorded.  On infusion days, blood pressure will be measured at 0 h (pre-dose), 30 min (mid-infusion), 60 min (end of infusion), and 1 h and 2 hours after the end of copanlisib infusion   Note: a window of ±15 min is allowed for all BP measurements, except for the 0 h (pre-dose) measurement, which may happen any time prior to infusion on the day of treatment.
 
 
4.4.[ADDRESS_428872] be fasting prior to sampling according to local standards. If a patient can’t adhere to fasting requirements, the evaluation of lipid-panels including triglycerides is considered not feasible.  
 Management of hyperlipi[INVESTIGATOR_345301]. Goals of therapy are to keep fasting triglycerides < 300 mg/dL (3.4 mmol/L) and low-density lipoproteins (LDL) < 190 mg/dL (4.9 mmol/L) (lower LDL depending on cardiovascular risk) in patients with a life expectancy >1 year. The goals for fasting triglycerides can be raised to < 500 mg/dL (5.6 mmol/L) for patients with life expectancy <1 year (31). 
 Although there is a paucity of data on the effects of hyperlipi[INVESTIGATOR_345302], 
these goals have been chosen to decrease risk of established complications of hypertriglyceridemia (pancreatitis) and hypercholesterolemia (cardiovascular events). For evaluation of lipid-panels including triglycerides the patient would be required to be fasted for 11 hours prior to sampling. For patients who cannot adhere to these fasting requirements the evaluation of lipid-panels including triglycerides and determination of 
J
1887/Version 7.0 / January 27, 2023 33 tre
atment is considered as not feasible 
 
[IP_ADDRESS]  Opportunistic Infection (OI) Monitoring 
 
In addition to the weekly clinical review and laboratory tests outlined in the schedule of 
assessment, the following should be performed in all patients prior to IV infusion of copanlisib: 
 Eva
luation of any new onset or worsening of pulmonary symptoms (i.e. cough, 
dyspnea or fever) that includes a lung examination at each visit prior to infusion  
 L
abs: WBC, Lymphocyte count, CD4 (for patients with signs of infection), blood 
cultures (per local SOC if patient develops febrile neutropenia or ANC CTCAE of grade 4), PCR for CMV (monthly for first 6 months of treatment and every 3 months thereafter) 
- Note: If PCR test for CMV > 500 IU/mL, treatment should be delayed until level reduces to ≤ 500 IU/mL. Treatment of CMV should be initiated based on local SOC. Re-treatment with copanlisib will be allowed without dose reduction once PCR test for CMV is ≤ 500 IU/mL.  
Enhanced monitoring when prior medical history or laboratory parameters could be associated with one of the following risk factors:  
 I
ntensive chemotherapy (≥ 2 lines of myelosupressive cytotoxic therapy) 
 History
 of CMV, herpes 
 History
 of lower respi[INVESTIGATOR_1092], history of  immunodeficiency in the 
last 12 months 
 Ly
mphocytes count < 500 while on treatment in clinical study 
 
For patients with identified risk factors and those who developed OI, additional assessments will include: 
 CD4 a
nd CD8 count and ratio, CRP, blood cultures  
 Any
 additional laboratory and diagnostic methods according to local SOC 
reported as unscheduled laboratory and diagnostic methods of assessment 
 Rad
iological imaging (i.e. CXR or CT Scans) 
 
Note: Treatment of developed OI should be based on local standards of care (SOC).  Prophylaxis of OI  Mandatory prophylactic therapy is not recommended in all patients: 
 Rev
iew of Copanlisib data do not support risk benefit ratio favoring prophylaxis 
in all patients  
 Ma
ndatory prophylaxis may cause a  higher risk of side effects associated with 
supportive treatment where no risks factors are present  
 Curr
ently implemented schedule of assessment, and additional enhancements 
provide frequent monitoring and flexibility for prophylaxis based on local SOC 
 Although not mandated in all patients, OI prophylaxis may be initiated at the discretion of the treating investigator’s judgment of the benefit/risk ratio in any patient, irrespective 
J
1887/Version 7.0 / January 27, [ADDRESS_428873] be reported as concomitant medications. 
 
Prophylactic treatment of OI should be initiated based on SOC in patients when high risk 
factors are identified (see above risk factors).  For example: Bactrim or equivalent, Acyclovir or equivalent. Treatment, dosage and route of administration must be reported as concomitant medications. 
 
4.4.5 Prohibited and Restricted Therapi[INVESTIGATOR_345303] (including retreatment for post-complete response relapse) of this trial: 
 Any non-study anticancer or immunotherapy agent 
 Any non-study investigational agents  
 Radiation therapy
  
o No
te:  Radiation therapy to a symptomatic solitary lesion or to the brain 
may be allowed at the investigator’s discretion.   
 Live vaccines within [ADDRESS_428874] dose of study treatment and while 
participating in the study.  Examples of live vaccines include, but are not limited 
to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally 
killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., 
FluMist®) are live attenuated vaccines and are not allowed.  
 Systemic glucocorticoids for any purpose other than to modulate symptoms from 
an adverse event of suspected immunologic etiology.  Steroid treatment should be 
completed at least 14 days prior to resuming study-related treatments. The use of physiologic doses of corticosteroids may be approved after consultation with the Protocol Chair. 
 Strong inhibitors or inducers of CYP3A4/5 (see Table 7  below for examples) 
 Medications that carry a strong risk for QT prolongation 
 Herbal medications/preparations except for vitamins (see Table 7  below for 
examples) 
 Anti-arrhythmic therapy other than beta blockers or digoxin 
 
Table 7: List of prohibited medications during the study
 
Cat
egory Drug name 
[CONTACT_345347]3A 
Inhibitors Voriconazole, boceprevir, clarithromycin, cobicistat, conivaptan, 
danoprevir/ritonavir, eltegravir/ritonavir, grapefruit juice, 
indinavir/ritonavir, itraconazole, ketoconazole, 
lopi[INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, nelfinavir, 
posaco
nazole, ritonavir, saquinavir, saquinavir/ritonavir, 
J
1887/Version 7.0 / January 27, 2023 35 telapr
evir, telithromycin, tipranavir/ritonavir, troleandomycin, 
Strong
 CYP3A 
Inducers Avasimibe, carbamazepi[INVESTIGATOR_050], mitotane, phenobarbital, phenytoin, 
rifabutin, rifampin (rifampi[INVESTIGATOR_2513]), St. John's wort (hypericum 
perforatum) 
H
erbal Preparations/ 
Medications Herbal preparations/medications are prohibited throughout the 
study. These herbal medications include, but are not limited to: St. 
John’s wort, Kava, ephedra (ma huang), ginkgo biloba, 
dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, and 
ginseng. Patients should stop using these herbal medications [ADDRESS_428875] dose of study drug  
 
Par
ticipants who, in the assessment by [CONTACT_093], require the use of any of the 
aforementioned treatments for clinical management should be removed from the study.  All 
treatments that the Investigator considers necessary for a participant’s welfare may be administered at the discretion of the Investigator in keepi[INVESTIGATOR_77981].  The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician.  However, the decision to continue the participant on study treatment requires the mutual agreement of the investigator, the Sponsor and the participant. 
There are no prohibited therapi[INVESTIGATOR_3927]-Treatment Follow-up Phase. 
 4.4.6 Acceptable Concomitant Medications 
 
All treatments that the investigator considers necessary for a participant’s welfare may be administered at the discretion of the investigator in keepi[INVESTIGATOR_77981].  All concomitant medication will be recorded on the case report form (CRF) including all prescription, over-the-counter (OTC), herbal supplements, and IV medications and fluids.   
Permitted concomitant therapy 
 Standard therapi[INVESTIGATOR_39674] 
 Treatment with non-conventional therapi[INVESTIGATOR_014] (for example herbs or acupuncture), and 
vitamin/mineral supplements is acceptable provided that they do not interfere with the study endpoints, in the opi[INVESTIGATOR_689]. St John’s Wort is not permitted. 
 Bisphosphonates 
 Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that their medication dose and INR/PTT is stable. Close monitoring is recommended according to standard of care. If either of these values is above the therapeutic range, the doses should be modified and the assessments should be repeated weekly until it is stable. 
 Antiemetics: Prophylactic anti-emetics may be administered according to standard practice. The routine use of standard antiemetics, including 5-HT3 blockers, such as 
J
1887/Version 7.0 / January 27, 2023 36 g
ranisetron, ondansetron, or an equivalent agent, is allowed as needed. The use of 
corticosteroids as antiemetics prior to copanlisib administration will be not allowed. 
 Palliative and supportive care for the other disease-related symptoms and for toxicity 
associated with treatment will be offered to all patients in this trial. 
 Patients may receive palliative and supportive care for any underlying illness 
 Palliative irradiation shall be permitted provided that: 
o In the opi[INVESTIGATOR_871], the patient does not have PD. 
o The radiation field does not encompass a target lesion 
o The radiation field does not encompass a lung field (to reduce the risk of pneumonitis). 
 Low-dose aspi[INVESTIGATOR_248] (maximum 100 mg/day) and low-dose heparin are permitted. 
 Patients taking narrow therapeutic index medications should be monitored proactively, if these medications cannot be avoided. These medications may include quinidine, cyclosporine, and digoxin 
 Calcium channel blockers to control pre-existing hypertension. Non-dihydropyridine calcium channel blockers (Verapamil and diltiazem) are permitted.  
 Short term (up to 7 days) systemic corticosteroids above 15 mg prednisone or equivalent will be allowed for the management of acute conditions (e.g. treatment of non-infectious pneumonitis).  
 Therapeutic drugs known to be sensitive substrates of the renal drug transporter MATE2K (e.g. metformin
, 
cimetidine, procainamide and N methylnicotinamide ) 
need to 
be used with caution. Metformin should be interrupted for [ADDRESS_428876] media. Please see prescribing information for further information.  
4.5 Duration of Therapy and Criteria for Removal from Study Treatment  
 
In the absence of treatment delays due to adverse event(s), treatment may continue indefinitely until one of the following criteria applies.  The reason for study treatment removal and the date the patient was removed must be documented in the Case Report Form.   A participant must be discontinued from study treatment but continue to be monitored in the study follow-up for any of the following reasons: 
 The participant  or participant’s legally acceptable representative requests to discontinue study treatment 
 Confirmed radiographic disease progression  outlined in Section [ADDRESS_428877] of the patient.  If subsequent imaging confirms progression, the patient’s date of progression will be the date of first progression 
 Clinical progression or deterioration 
J
1887/Version 7.0 / January 27, 2023 37  Prog
ression or recurrence of any malignancy, or any occurrence of another malignancy 
that requires active treatment 
 Unacceptable adverse experiences as described in Section 4.4. [ADDRESS_428878] be 
approved by [CONTACT_9533]. 
 The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_120484]/or sponsor, placed the participant at unnecessary risk from continued administration of study treatment. 
 Investigator’s decision to withdraw the subject 
 The participant has a confirmed positive serum pregnancy test 
 Noncompliance with study treatment or procedure requirements 
 
4.6 End of Treatment (EOT) Visit 
 After a patient is discontinued from treatment, an End of Treatment (EOT) Visit should be performed approximately [ADDRESS_428879] infusion of study medication (or within [ADDRESS_428880]).  Procedures and assessments performed at this visit and beyond should follow the guidelines described in the Study Calendar in Section 8 as appropriate.  The patient will be monitored for adverse events 
up to the mandatory Off Study/Safety Follow-Up Visit.   
 
4.[ADDRESS_428881] and be contact[CONTACT_457] 3 months (+/- 2 weeks) to monitor OS for up to [ADDRESS_428882]-study anti-neoplastic treatment will be collected if new treatment is initiated.    Subjects who are discontinued from the study treatment due to an unacceptable drug-related AE will be monitored for safety until the resolution of the AE to ≤ grade 1, or stabilization, or until initiation of a new therapy for their cancer, whichever occurs first.   All subjects will be followed for at least [ADDRESS_428883] dose of study drug for the development of AEs. SAEs that occur within 100 days (+ 14 day reporting window) of the last infusion of nivolumab or before initiation of a new antineoplastic treatment should also be followed and recorded. 
  
J
1887/Version 7.0 / January 27, 2023 38 5. AD
VERSE EVENTS:  LIST AND REPORTING REQUIREMENTS 
 
This study will use the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting that can be found at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.   
 I
nformation about all adverse events, whether volunteered by [CONTACT_423], discovered by 
[CONTACT_424], or detected through physical examination, laboratory test or other means, will be collected, recorded, and followed as appropriate.   The PI [INVESTIGATOR_38202], protocol compliance, and identification, grading, coding, and required reporting of all anticipated and unanticipated adverse events and protocol problems. Although this responsibility is usually shared among the PI, research nurse, and data manager, the PI [INVESTIGATOR_38203].  
5.1 Definitions 
 
5.1.1 Adverse Event 
 
An adverse event (AE) is defined as any undesirable sign, symptom or medical condition occurring after starting the study drug (or therapy) even if the event is not considered to be related to the study. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver) or the abnormal results of an investigation (e.g. , 
laboratory findings, electrocardiogram). Medical conditions/diseases present before starting the study treatment are only considered adverse events if they worsen after starting the study treatment (any procedures specified in the protocol). Symptoms / medical conditions occurring before starting the study treatment but after signing the informed consent form will not be recorded as AEs. Additionally, expected progression of the disease being studied will not be recorded as an adverse event.    Laboratory abnormalities:  Laboratory abnormalities present at the screening visit will be 
recorded as pre-treatment signs and symptoms in a medical history CRF. After study treatment administration, all grade 3 and 4 clinical laboratory results that represent an increase in severity from baseline will be reported as adverse events. A grade 1 or 2 clinical laboratory abnormality should be reported as an adverse event only if it is considered clinically significant by [CONTACT_093], induces clinical signs or symptoms, or requires therapy. 
 
5.1.2 Serious Adverse Event (SAE) 
 
A serious adverse event (SAE) is an adverse event which:  
 Results in death  
 Is life threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)  
J
1887/Version 7.0 / January 27, 2023 39  Req
uires inpatient hospi[INVESTIGATOR_312] 
(see note below for exceptions) > 24 hours 
 Results in persistent or significant disability/incapacity  
 Is a congenital anomaly/birth defect (note: reports of congenital anomalies/ birth 
defects must also be reported on the Pregnancy Supplemental Form)  
 Is an important medical event (defined as a medical event(s) that may not be 
immediately life-threatening or result in death or hospi[INVESTIGATOR_313], based upon 
appropriate medical and scientific judgment, may jeopardize the subject or may require intervention [e.g., medical, surgical] to prevent one of the other serious outcomes listed in the definition above.). Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]). 
 Suspected transmission of an infectious agent (e.g. pathogenic or nonpathogenic) via the study drug is an SAE. 
Although pregnancy, overdose, potential drug-induced liver injury (DILI), and new cancers are not always serious by [CONTACT_8661], these events must be handled as SAEs. 
Drug induced liver injury (DILI) is defined as:  
An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is greater than or 
equal to 2X the upper limit of normal and, at the same time, an alkaline 
phosphatase lab value that is less than 2X the upper limit of normal, as determined by [CONTACT_13149]-specified laboratory testing or unscheduled laboratory testing.* 
 *Note:  These criteria are based upon available regulatory guidance documents. 
The
 purpose of the criteria is to specify a threshold of abnormal hepatic tests that 
may require an additional evaluation for an underlying etiology.  
 
Events not considered to be serious adverse events are hospi[INVESTIGATOR_314]:  
 Admissions as per protocol for a planned medical/surgical procedure or to facilitate a procedure 
 Routine health assessment requiring admission for baseline/trending of health status 
(e.g., routine colonoscopy)  
 Medical/surgical admission for purpose other than remedying ill health state and was 
planned prior to entry into the study. Appropriate documentation is required in these cases  
 Admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, care-giver respi[INVESTIGATOR_040], family circumstances, administrative). 
 
5.1.[ADDRESS_428884] be reported as SAEs. In the event of overdose, the participant should be observed closely for signs of toxicity.  Appropriate supportive treatment should be provided if clinically indicated. 
J
1887/Version 7.0 / January 27, 2023 40  
5.2 Re
lationship 
 
The relationship of an AE to the administration of the study drug is to be assessed by [CONTACT_70723]:  
 No (unrelated, not related, no relation):  The time course between the administration of study drug and the occurrence or worsening of the adverse event rules out a causal relationship and another cause (concomitant drugs, therapi[INVESTIGATOR_014], complications, etc.) is suspected.  
 
 Yes (related): The time course between the administration of study drug and the 
occurrence or worsening of the adverse event is consistent with a causal relationship and no other cause (concomitant drugs, therapi[INVESTIGATOR_014], complications, etc.) can be identified.  
 The following factors should also be considered:  
 The temporal sequence from study drug administration - The event should occur after the study drug is given. The length of time from study drug exposure to event should be evaluated in the clinical context of the event.  
 Underlying, concomitant, intercurrent diseases - Each report should be evaluated in the 
context of the natural history and course of the disease being treated and any other 
disease the subject may have.  
 Concomitant medication - The other medications the subject is taking or the treatment the subject receives should be examined to determine whether any of them might be recognized to cause the event in question.  
 Known response pattern for this class of study drug - Clinical and/or preclinical data may indicate whether a particular response is likely to be a class effect.  
 Exposure to physical and/or mental stresses - The exposure to stress might induce adverse changes in the recipi[INVESTIGATOR_23567] a logical and better explanation for the event.  
 The pharmacology and pharmacokinetics of the study drug - The known pharmacologic properties (absorption, distribution, metabolism, and excretion) of the study drug should be considered.  
5.3 Assessment of Grade      
 
The investigator will make an assessment of grade for each AE and SAE reported during the study, which will be recorded in the CRF. The assessment will be based on the National Cancer Institute’s CTCAE (Version 5.0) and graded as shown below: 
 
 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated 
 Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living 
 Grade 3: Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-
care activities of daily living 
J
1887/Version 7.0 / January 27, 2023 41  Gr
ade 4: Life-threatening consequences; urgent intervention indicated 
 Grade 5: Death related to AE 
 
Any AE that changes in grade during its course will have each change of grade recorded on 
the adverse event case report forms. 
 
5.4 Expectedness 
 
Unexpected adverse event: An adverse event, which varies in nature, intensity or frequency 
fr
om information on the investigational drug/agent provided in the Investigator’s Brochure, 
package insert or safety reports. Any adverse event that is not included in the informed consent is considered “unexpected”.   Expected (known) adverse event: An adverse event, which has been reported in the 
I
nvestigator’s Brochure. An adverse event is considered “expected”, only if it is included in 
the informed consent document as a risk. 
 
5.5 Handling of Expedited Safety Reports 
 
In accordance with local regulations, the IND Sponsor will notify investigators of all SAEs that are unexpected (i.e. not previously described in the Investigator Brochure), and definitely, probably, or possibly related to nivolumab or copanlisib. This notification will be in the form of an expedited safety report (ESR) that is to be faxed to the investigators and the study coordinators. Upon receiving such notices, the investigator must review and retain the notice with the Investigator’s Brochure and where required by [CONTACT_427], the investigator will submit the ESR to the appropriate IRB. The investigator and IRB will determine if the informed consent requires revision. The investigator should also comply with the IRB procedures for reporting any other safety information.  
 
5.6 Reporting 
 
5.6.1 General 
 
All adverse events (both expected and unexpected) will be captured on the appropriate study-
specific case report forms (CRFs).   Adverse events experienced by [CONTACT_345326], throughout the study, and will only be followed for 30 days (or within [ADDRESS_428885]) unless related to the study drug(s). Adverse events related to the study drug(s) will be monitored for resolution of toxicity to ≤ grade 1, stabilization, or determined to be irreversible by [CONTACT_093].  
 
SAEs that occur following the subject’s written consent to participate in the study through 
100 days (+ 14 day reporting window) after the last infusion of study drug (or within [ADDRESS_428886]) will be collected and reported. 
 
J1887/Version 7.0 / January 27, [ADDRESS_428887] be followed by [CONTACT_178558]. 
 
SAE reports and any other relevant safety information are to be sent to: 
 
After the initial SAE report, the investigator is required to proactively follow each subject and provide further information to the safety department in regards to the subject’s condition. 
  
All SAE(s) will be followed until: 
 Resolution 
 The condition stabilizes 
 The event is otherwise explained 
 The subject is lost to follow-up 
 Death 
 
As soon as relevant information is available, a follow-up SAE report will be submitted to the IND Sponsor, BMS, and Bayer.  The Sponsor will reconcile the clinical database SAE cases (case level only) transmitted to BMS Global Pharmacovigilance . 
 The Investigator will request from BMS GPV&E the SAE reconciliation report and include the BMS protocol number every 3 months and prior to data base lock or final data summary. 
 GPV&E will send the investigator the report to verify and confirm all SAEs have been transmitted to BMS GPV&E. 
 The data elements listed on the GPV&E reconciliation report will be used for case identification purposes. If the Investigator determines a case was not transmitted to BMS GPV&E, the case should be sent immediately to BMS 
 5.6.[ADDRESS_428888] (spontaneously reported to them), including the pregnancy of a male subject's female partner who has provided written consent to provide information regarding pregnancy, that occurs during the trial or within [ADDRESS_428889] be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious adverse events (Important Medical Events). Pregnancy and non-serious pregnancy outcomes should be reported as Events of Clinical Interest. If the pregnancy continues to term, the outcome (health 

J1887/Version 7.0 / January 27, [ADDRESS_428890] (IRB)  
 
Participating sites will be responsible for reporting to their IRB. All serious adverse events 
will be reported to the IRB per institutional standards. Upon receipt, follow-up information 
will be given to the IRB (as soon as relevant information is available) per institutional 
standards. 
 
5.6.4 Food and Drug Administration (FDA) 
 
All reporting to the FDA will be completed by [CONTACT_9533]. 
 
[IP_ADDRESS]  Expedited IND Safety Reports: 
 
7 Calendar-Day Telephone or Fax Report :   
The IND Sponsor is required to notify the FDA of any fatal or life-threatening adverse event that is unexpected and assessed by [CONTACT_38241].  Such reports are to be telephoned or faxe  to the 
FDA within [ADDRESS_428891] learning of the event.    15 Calendar-Day Written Report :   
The IND Sponsor is required to notify the FDA of any serious adverse event that is unexpected and possibly related to the investigational agent in a written IND Safety Report.    Written IND Safety Reports should include an Analysis of Similar Events in accordance with regulation 21 CFR § 312.32.  All safety reports previously filed with the IND concerning similar events should be analyzed.  The new report should contain comments on the significance of the new event in light of the previous, similar reports.   Written IND safety reports with Analysis of Similar Events are to be submitted to the FDA within [ADDRESS_428892] learning of the event. Follow-up information will be submitted to the FDA as soon as relevant information is available. 
 
[IP_ADDRESS]  IND Annual Reports 
 
In accordance with the regulation 21 CFR § 312.33, the IND Sponsor shall within [ADDRESS_428893] submit a brief report of the adverse events and progress of the investigation.  Please refer to Code of Federal Regulations, 21 CFR § 312.[ADDRESS_428894] of the elements required for the annual report.  All IND annual reports will be submitted to the FDA by [CONTACT_9533].  
  

J
1887/Version 7.0 / January 27, [ADDRESS_428895] in accordance with the protocol and any applicable laws and regulations.  6.1.2 Mode of Action 
 Nivolumab is a fully human monoclonal immunoglobulin (Ig) G4 antibody that binds to the PD-1 cell surface membrane receptor, a negative regulatory molecule expressed by [CONTACT_93247] T and B lymphocytes. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens.   6.1.3 Description 
 
Nivolumab Injection, 100 mg/vial (10 mg/mL) is a clear to opalescent, colorless to pale, yellow liquid; light (few) particulates may be present. The drug product is a sterile, nonpyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriamine pentaacetic acid and polysorbate 80 (Tween™ 80), pH 6.0 and includes a 0.7-mL overfill to account for vial, needle, and syringe (VNS) holdup. It is supplied in 10-cc type I flint glass vials, stoppered with butyl rubber stoppers and sealed with aluminum seals.  6.1.4 Packaging and Labeling Information 
 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment.   6.1.5 Preparation 
 Nivolumab injection should be diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to protein concentrations as low as 1 mg/mL. Care must be taken to assure sterility of the prepared solution as the product does not contain any anti-microbial preservative or bacteriostatic agent. No incompatibilities between nivolumab and polyolefin bags have been observed. Recommended safety measures for preparation and handling of nivolumab include laboratory coats and gloves. Detailed instructions on the preparation of nivolumab for administration will be provided in the Investigator’s Brochure.  6.1.6 Storage and Handling Requirements 
 
J
1887/Version 7.0 / January 27, [ADDRESS_428896] 
be stored at a temperature of 2°C to 8°C and should be protected from light and freezing. 
If stored in a glass front refrigerator, vials should be stored in the carton. Receipt and dispensing of trial medication must be recorded by [CONTACT_131895]. Clinical supplies may not be used for any purpose other than that stated in the protocol.  6.1.[ADDRESS_428897] be completed within 24 hours of preparation. If not used immediately, the infusion solution may be stored under refrigeration conditions (2°-8°C, 36°-46°F) for up to 24 hours, and a maximum of 8 hours of the total 24 hours can be at room temperature (20°-25°C, 68°-77°F) and room light. The maximum 8-hour period under room temperature and room light conditions includes the product administration period.  6.1.8 Route of Administration 
 Nivolumab is to be administered as a 30 minute IV infusion, using a volumetric pump with a 0.2/0.22 micron in-line filter at the protocol-specified dose. It is not to be administered as an IV push or bolus injection. At the end of the infusion, flush the line with a sufficient quantity of normal saline.   6.1.9 Returns and Reconciliation 
 
The investigator is responsible for keepi[INVESTIGATOR_345304], the amount dispensed to and returned by [CONTACT_345327].   Upon completion or termination of the study, all unused and/or partially used investigational product will be destroyed at the site per institutional policy. It is the Investigator’s responsibility to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. BMS will be notified of all destruction of study drug.  
6.[ADDRESS_428898] in accordance with the protocol and any applicable laws and regulations.  6.2.2 Mode of Action 
 Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant and potent activity against the PI3K-δ and PI3K-α isoforms. The PI3K pathway is a 
J
1887/Version 7.0 / January 27, [ADDRESS_428899] is expected to lead to impaired cellular 
uptake of glucose, with a subsequent reactive rise in plasma insulin and glucose levels.  
 
6.2.3 Description 
 Copanlisib is supplied as lyophilized preparation in a 6-mL injection vial. The total amount of BAY 80-6946 per vial is 60 mg. The solution for IV infusion is obtained after reconstitution of the lyophilisate with 0.9% sodium chloride solution. 
 
6.2.4 Packaging and Labeling Information 
 Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. Open label kits will be provided for patient dosing. This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. 
 
6.2.[ADDRESS_428900] be stored between +2°C and +8°C and should not be transported above +30°C. Clinical supplies must be stored in a secure, limited-access location.  Receipt and dispensing of trial medication must be recorded by [CONTACT_131895]. Clinical supplies may not be used for any purpose other than that stated in the protocol. 
 
6.2.7 Stability 
 Refrigeration is not required if reconstituted copanlisib is used immediately (within max of 4 hours). If not used immediately, store reconstituted solution in the vials or in the infusion bag at +2°C to +8°C (36°F to 46°F). Allow the product to adapt to room temperature after refrigeration. It takes approximately [ADDRESS_428901] sunlight.  
 
6.2.8 Route of Administration 
 Copanlisib is administered in a normal saline solution, intravenously, over 1 h.  No intravenous glucose preparations should be administered on the days of infusion. 
6.2.9 Returns and Reconciliation 
 
The investigator is responsible for keepi[INVESTIGATOR_345305] 
J1887/Version 7.0 / January 27, 2023 47 from Bayer or designee, the amount dispensed to and returned by [CONTACT_345328].   Upon completion or termination of the study, all unused and/or partially used investigational product will be destroyed at the site per institutional policy. It is the Investigator’s responsibility to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, 
local and institutional guidelines and procedures, and provided that appropriate records of 
disposal are kept. 
 
 7. CORRELATIVE/SPECIAL STUDIES 
 
Detailed instructions for collection, processing, and storage of tumor and blood samples are 
provided in the Laboratory Manual. Results from the sequencing studies will not be released 
to the patients. These studies are for research purposes only and are not using a clinically 
validated platform. 
  
7.[ADDRESS_428902] paired biopsies – one prior to treatment and one after six weeks on therapy (4-6 cores per time point).  This will be prior to Cycle 2 Day 15 treatment, after two doses of nivolumab and three or five doses of copanlisib (depending on the dose level).  Patients will also be asked for an optional biopsy at the time of progression.    Tumor biopsy will not be performed if the tumor is not accessible or if biopsy is considered not in the patient’s best interest.    Attempts will be made to obtain archived tissue samples from all subjects.  Archived FNA biopsy samples do not contain sufficient tissue and will not be collected.    We will assess tumor immune infiltrate using immunohistochemistry (IHC) and flow cytometry of disaggregated tumor samples. Expression of PD-L1 and of a series of biomarkers will be assessed by [CONTACT_4658]. CD8+ T cells will be enriched by [CONTACT_345329] T cell exhaustion and 
cytokine production. We will also use single cell RNASeq for an unbiased assessment not only of cellular composition but also of functional status as assessed by [CONTACT_345330]. From single cell expression data, we hope to identify gene expression profiles of tumor cells that are correlated with response to therapy. 
Tumor Sample Requirements:  
Slides 
H&E 
10 unstained FFPE 
Tissue 
50mg fresh (flow cytometry) 
50mg fresh ( ex vivo  T cell stimulation) 
25 mg fresh/frozen (single cell RNASeq) 

J
1887/Version 7.0 / January 27, 2023 48  
7.2 P
eripheral Blood Mononuclear Cells (PBMCs)  
 
Up to [ADDRESS_428903] a known-activating mutation of PIK3 as defined in Table 8 .  Additional mutations may be added to this definition in the 
face of emerging discovery.  
Table 8 
– Ac
tivating PIK3 Mutations  
G1
06R 
R108H  
P124
L 
V3
44G 
N3
45K 
C420R  
E54
2K 
E54
3_I459del  
E54
5K, E545A, E545Q, E545G  
Q5
46K 
Q5
46R, Q546P  
H1
047R, H1047L  
G1
049R  
 
J1887/Version 7.0 / January 27, [ADDRESS_428904] of copanlisib on tumor immune subpopulations.   
Expected results include 1) an increase in the number of infiltrating CD8+ T cells following 
treatment with copanlisib and nivolumab and/or 2) a decrease in immunosuppressive cells 
including CD4+, FOXP3+ Treg cells or functional myeloid derived suppressor cells 
(MDSCs).  Objectives related to tumor immune subsets will be accomplished by [CONTACT_345331], and tissue prioritized as below. Intended comparisons are between paired 
biopsy specimens from the same patient, where a change in populations can be correlated 
with treatment, as well as inter-patient comparisons for correlation with clinical response.   
 
1. Multiplex IHC/IF  
A series of biomarkers will be assessed on tissue from this study. A sample of immune and 
other markers in Table 9  will be the stains of high priority for these exploratory 
investigations, in order of priority based on amount and quality of tissue obtained. Briefly, 
tumor samples will be stained on a quantitative multiplex immunohistochemical platform 
developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center that was 
previously published22. This technology incorporates a computational image processing 
workflow, including image cytometry, that enables simultaneous evaluation of 12 
biomarkers in one formalin fixed paraffin-embedded tissue section. This platform is readily 
adaptable to assess a variety of markers including lymphoid and myeloid lineage markers, 
in addition to those listed in Table 9 . After staining, slides will be analyzed in the Cell 
Imaging Core Facility at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to 
quantitate the percentage and intensity of cells for each marker(s) in the TME. The 
biomarker data will be captured for samples according to a digital image workflow. Briefly, 
this encompasses three steps: image preprocessing, visualization, and quantitative image 
analysis using state-of-the-art software in the Core Lab. This system allows for true 
quantitative data on dual staining in patient samples. These IHC and IF analyses will be 
conducted under the guidance o  To ensure the rigor of these analyses, 
samples will be batch run when possible, with appropriate positive (i.e. tonsil tissue for 
immunostains) and negative controls (secondary Ab only) along with serial sections from 
a single archival colon carcinoma tumor specimen as a qualitative control to for intensity 
and any batch-to-batch variability between reagents used in IHC or IF assays. 
 
Table 9 - Planned Immunohistochemical (IHC) and Immunofluorescence (IF) analysis 
(*denotes primary biomarker) 
Immunohistochemistry  Immunofluorescence   
CD8*, CD4, PD-L1, PTEN CD8+, Ki67+, CD8+Nur77+, 
CD4+FoxP3+  Priority 1 
CD11c, CD19, CD68, CD163, CTLA4, 
PD-1, PD -L2, IDO1, LAG3 , p-AKT  CD33+S100+, CD4+IL-17+ Priority 2 
 
2. Flow cytometry  
When adequate fresh tissue can be obtained, tumor will be disaggregated using a 
combination of enzymatic and mechanical disruption23. Resulting suspension will be 
analyzed by [CONTACT_345332] 10 . Included in this panel is 
analysis of a subset of CD8+ T cells identified by 

J
1887/Version 7.0 / January 27, 2023 50 (CD
8+Ki67+) that displays a proliferative burst after PD-1 blockade and may be a potential 
bioma
rker of response to anti-PD-1 therapy24.  P
opulations will be normalized to tumor 
we
ight using counting beads.  
 
Table 10  - Planne
d markers for flow cytometry of disaggregated tumor biopsies. 
Ce
ll population  M
arker  
CD8+
 T cell  CD8, 
GZMB, PD -1, T
im3, Lag3, 2B4, Ki67  
Reg
ulatory CD4+ FOXP3+ T Cell  CD4, 
FOXP3  
MD
SC CD11
b, HLA-DR, CD14, CD15, CD33, 
L
in-(CD
3/14/15/19/56)  
NK CD56  
B
 cell CD19  
 
3. Sing
le cell/nuclei RNASeq  
Sing
le cell RNASeq will provide an unbiased assessment of cellular composition and of 
fu
nctional status as assessed by [CONTACT_345333]. Single cell 
se
quencing of tumor biopsies will be performed using droplet technology (10X genomics), 
wh
ereby [CONTACT_345334] a unique transcriptome 
ba
rcode applied prior to lysis and whole transcriptome amplification. High-quality data 
will 
be generated from 6-10,[ADDRESS_428905] analysis 
of
 the tumor microenvironment.  Initial analysis based on signature [CONTACT_345348]. non-tumor (stroma, immune cell) populations. Subsequent 
a
nalyses will include reconstruction of TCR sequences and tracking of TCR clones 
thro
ughout subpopulations25,
 arrangement of cells in pseudotemporal space with 
Mono
cle26, 
differential expression analysis based on mixture models to account for the 
zero-infla
tion of single cell transcriptional data27, a
nd calculation of cell-by-cell gene-set 
sig
nature scores28 to 
probe for pathway and phenotype-level differences between 
subpo
pulations. 
 
7.5.[ADDRESS_428906] of Copanlisib on CD8 T cell function 
CD8
+ T cells are expected to not only increased in number in copanlisib-treated tumors 
but 
to also be more functional, as measured by [CONTACT_345335] 
e
xpression of inhibitory ligands.  CD8+ T cells will be enriched by [CONTACT_345336]
m disaggregated tumor samples and stimulated ex vivo.  Production of cytokines IFNγ 
a
nd TNFα will be measured by [CONTACT_4133].  Inhibitory ligands commonly expressed 
on 
exhausted T cells including PD-1, Tim3, Lag3, and 2B4 will be measured by [CONTACT_345337].   
 
7.5.[ADDRESS_428907] methods using density gradient 
J1887/Version 7.0 / January 27, [ADDRESS_428908] approximately 40 paired biopsies (75% success rate based on previous 
studies) as well as ~6-12 time points for blood draws to assess changes in circulating immune 
parameters. We estimate 20% of patients would allow a progression biopsy. 
  

J
1887/Version 7.0 / January 27, 2023 52 8. STUDY
 SCHEDULE 
8.1 Study Calendar – Phase I 
 B
aseline1 Tr
eatment (1 cycle = 28 days) EOT21 Su
rvival 
Follow-Up22  
Q12 
weeks  
(± 2 weeks)  Cycle
 1 Cycle 2 and higher 
 
P
rocedure (-28 to 0)  D1 
(±3 
day
s) D8 
(+1 
day) D15 
(+3 
days) D1 
(±3 
days) D8 
(+1 
day) D15 
(+3 
days) 30 days (+/-4 
da
ys) after last  
study
 drug 
Ad
ministrative Procedures 
Inf
ormed Consent  X         
Inclusi
on/Exclusion Criteria  X         
De
mographics and Med Hx2 X         
C
opanlisib   X X X X  X X   
Niv
olumab   X   X     
P
ost-study anticancer therapy 
an
d survival status          X 
Clin
ical Assessments 
P
hysical Examination, ECOG3 X X X X X  X X  
Vital S
igns4 X X X X X X X X  
Blo
od Pressure (infusion days)5  X X X X X X   
Weigh
t X X   X   X  
Height
 (
may be from prior visit)  X         
R
eview Adverse Events   X X X X X X X  
C
on Med Review  X X X X X X X X  
L
aboratory Assessments  
C
BC with Differential6, 16 X X X X X  X X X  
C
hemistry Panel7, 16 X X X X X X X X  
Glu
cose8  X X X X X X   
He
moglobin A1C16 X    X9   X  
L
ipid Panel10, 16 X X X X X(ev
en 
c
ycles)    X  
T
SH11, 16 X X  X X  X X  
PT
, INR and aPTT16 X         
HBsAg
, HCV Ab, HIV12 X         
C
MV PCR13,16 X    X     
P
regnancy Test14, 16 X X   X   X  
Urin
alysis15, 16 X    X(ev
en 
c
ycles)      
Urin
e protein:creatinine ratio 
(UP
CR) X         
12-lead 
ECG  X       X  
MUG
A or echocardiogram17 X       X  
C
EA X X   X   X  
E
fficacy Assessments 
T
umor Imaging18 X    X(od
d 
c
ycles)    X  
T
issue and Blood for Correlative Studies 
Fresh
 Tumor Biopsy19 X      X X  
A
rchival Tumor Sample  X         
Blo
od for PBMC (180cc)20, 16  X  X X(od
d 
c
ycles)    X  
J
1887/Version 7.0 / January 27, 2023 53  B
aseline1 Tr
eatment (1 cycle = 28 days) EOT21 Su
rvival 
Follow-Up22  
Q12 
weeks  
(± 2 weeks)  Cycle
 1 Cycle 2 and higher 
 
P
rocedure (-28 to 0)  D1 
(±3 
day
s) D8 
(+1 
day) D15 
(+3 
days) D1 
(±3 
days) D8 
(+1 
day) D15 
(+3 
days) 30 days (+/-4 
da
ys) after last  
study
 drug 
Blo
od for plasma (20 cc) 20,
 16  X  X X(od
d 
c
ycles)    X  
 
In 
order to minimize the need for research-only in-person visits, telemedicine visits may be substituted 
for 
in-person clinical trial visits or portions of clinical trial visits where determined to be appropriate 
and 
where determined by [CONTACT_345338].  Prior to initiating 
telem
edicine for study visits the study team will explain to the participant, what a telemedicine visit entails 
and 
confirm that the study participant is in agreement and able to proceed with this method.  In the event 
telem
edicine is not deemed feasible, the study visit will proceed as an in-person visit.  Telemedicine visits 
w
ill be conducted using HIPAA compliant method approved by [CONTACT_345339].  
1. Baseline evaluations should occur within 28 days prior to registration, unless otherwise noted.  
No window applies to demographics, consent, or height at baseline.   
2. Includes history of lung disease, cardiovascular disease, diabetes, HIV, hepatitis B or C 
infection, and complete cancer history, including primary site of cancer, gross location of 
primary tumor, histology, histologic grade, date of initial diagnosis, date of metastatic diagnosis, prior cancer therapy regimens 
3. A complete physical exam will be performed at baseline; focused physical exams will be done 
thereafter. Physical exams and AE assessments can be done up to 3 days prior to dosing. 
4. Temperature, pulse, blood pressure, respi[INVESTIGATOR_697], and pulse oxygen will be collected at baseline, and prior to each dose of study drug, and at EOT visit.  
5. Blood pressure will be measured every 5-10 minutes prior to each copanlisib dose (no more than 
4 measurements) until there are 2 consecutive results ≤ 150/90 mmHg. If the blood pressure is 
≥ 150/90 mmHg, the investigator can consider a medical intervention e.g. administration of 
dihydropyridine calcium channel blocker), or delaying the infusion of the study drug. Blood 
pressure will be measured at pre-dose, 30 min (mid-infusion), 60 min (end of infusion), and 1h and 2h after the end of copanlisib infusion (±15 minute window for all BP measurements). 
6. CBC with differential includes: absolute neutrophil count, absolute lymphocyte count, absolute 
eosinophil count, and platelet count 
7. Chemistry panel includes: albumin, alkaline phosphatase, total bilirubin (direct bilirubin if total 
bili is > ULN), bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total 
protein, SGOT [AST], SGPT [ALT], sodium, LDH, magnesium, phosphorus, uric acid. 
Amylase and lipase to be down at screening and Day1 of every cycle. 
8. Fasting  glucose will be measured at 0h (pre-dose), and 1 hour (+/- 15 min) after completion of 
copanlisib infusion and subsequently if clinically indicated at the discretion of the investigator. 
NOTE: if patient needs to take a low glycemic meal on infusion days, then glucose test should 
be taken prior to meal intake. Glucose measurements may be done by [CONTACT_345340][INVESTIGATOR_17276].  
9. HbA1c to be tested at screening, on Day 1 of every three cycles (4, 7, 10, etc) starting at cycle 
4, and at the EOT visit 
10. HDL, LDL, triglycerides, total cholesterol; performed at Screen, Cycle 1 Day 1, Day 8, and Day 15; then Day 1 of every other cycle (starting at Cycle 2) 
J
1887/Version 7.0 / January 27, [ADDRESS_428909] is required 
15. Bilirubin, hemoglobin, glucose, ketones, leukocytes, nitrite, pH, color, protein, RBC and WBC 
count, and specific gravity.  Performed at baseline and Day 1 of every other cycle (starting at 
cycle2). 
16. Labs and research blood should be collected within a window of 3 days prior to dosing. Labs may be repeated prior to dosing if needed. 
17. MUGA scan or echocardiogram to measure LVEF; the method chosen at baseline must be the 
same throughout the whole study period (baseline and EOT); at EOT visit must be done if not 
previously done within 4 weeks 
18. Radiologic evaluations and tumor measurements will be performed at baseline (within 28 days 
of dosing), prior to each odd cycle (up to 1 week prior), and at End of Treatment visit.  If patient 
comes off study for reasons other than disease progression, subject may have additional 
radiologic evaluations every [ADDRESS_428910]/abdomen/pelvis with contrast will be used, however, non-contrast CT chest and MRI abdomen/pelvis will be done for patients with contrast allergies. 
19. Biopsy to be collected at baseline and [ADDRESS_428911] dose of study drug (± 3 days, but before Cycle 2 Day 15 study drug administration).  An optional biopsy may be performed at the time of progression. Approximately 6 core biopsy specimens will be obtained at each biopsy. 
20. Blood for PBMC and plasma will be collected at baseline/prior to first dose, [ADDRESS_428912] 4 weeks. 
22. Subjects who discontinue treatment will be followed (by [CONTACT_648], email or visit) every 12 weeks 
(± 2 weeks) after completion of EOT visit for up to 2 years or study closure to monitor overall 
survival.  Information on other cancer therapi[INVESTIGATOR_38207]. In 
addition, SAEs that occur within 100 days (+14 day reporting window) of the end of treatment or before initiation of a new antineoplastic treatment should also be followed and recorded. 
 
  
J
1887/Version 7.0 / January 27, 2023 55 8.2 Study Ca
lendar – Phase II 
 Scr
een1 Tr
eatment (1 cycle = 28 days) 
EOT21 
Su
rvival 
Follow-Up22  
Q12 
weeks  
(± 2 weeks)  Cycle
 1 Cycle 2 and higher 
P
rocedure D -28  
to 0 D1 
(±3 
days) D8 
(+1 
day) D15 
(+3 
days) D1 
(±3 
days) D8 
(±1 
day) D15 
(-1/+3 
days) 30 days 
(+/-4 d
ays) 
after last  
study drug  
Ad
ministrative Procedures  
Inf
ormed Consent  X         
Inclusi
on/Exclusion Criteria  X         
De
mographics and Med Hx2 X         
C
opanlisib   X X X X X X   
Niv
olumab   X   X     
P
ost-study anticancer therapy 
an
d survival status          X 
Clin
ical Assessments  
P
hysical Examination, ECOG3 X X  X X  X X  
Vital S
igns4 X X X X X X X X  
Blo
od Pressure (inf
usion days)5  X X X X X X   
Weigh
t X X   X   X  
Height  X         
R
eview Adverse Events   X X X X X X X  
C
on Med Review  X X X X X X X X  
L
aboratory Assessments  
C
BC with Differential6, 16 X X X X X  X X X  
C
hemistry Panel7, 16 X X X X X X X X  
Glu
cose8  X X X X X X   
He
moglobin A1C16 X    X9   X  
L
ipid Panel10, 16 X    X(ev
en 
c
ycles)    X  
T
SH11, 16 X X  X X  X X  
PT
, INR and aPTT16 X         
HBsAg
, HCV Ab, HIV12 X         
C
MV PCR13,16 X    X     
P
regnancy Test14, 16 X X   X   X  
Urin
alysis15, 16 X    X(ev
en 
c
ycles)      
Urin
e protein:creatinine ration 
(UP
CR) X         
12-lead 
ECG  X       X   
MUG
A or echocardiogram17 X       X   
C
EA X X   X   X  
E
fficacy Assessments  
T
umor Imaging18 X    X(od
d 
c
ycles)    X  
T
issue and Blood for Correlative Studies  
Fresh
 Tumor Biopsy19 X      X X  
A
rchival Tumor Sample  X         
Blo
od for PBMC (100cc)20
, 16  X  X X(od
d 
c
ycles)    X  
Blo
od for plasma (20 cc) 20,
 16  X  X X(od
d 
c
ycles)    X  
 
J
1887/Version 7.0 / January 27, 2023 56 In 
order to minimize the need for research-only in-person visits, telemedicine visits may be substituted 
for 
in-person clinical trial visits or portions of clinical trial visits where determined to be appropriate 
and 
where determined by [CONTACT_345338].  Prior to initiating 
telem
edicine for study visits the study team will explain to the participant, what a telemedicine visit entails 
and 
confirm that the study participant is in agreement and able to proceed with this method.  In the event 
telem
edicine is not deemed feasible, the study visit will proceed as an in-person visit.  Telemedicine visits 
w
ill be conducted using HIPAA compliant method approved by [CONTACT_345339].  
1. Baseline evaluations should occur within 28 days prior to registration, unless otherwise noted.  
No window applies to demographics, consent, or height at baseline.   
2. Includes history of lung disease, cardiovascular disease, diabetes, HIV, hepatitis B or C 
infection, and complete cancer history, including primary site of cancer, gross location of 
primary tumor, histology, histologic grade, date of initial diagnosis, date of metastatic diagnosis, prior cancer therapy regimens 
3. A complete physical exam will be performed at baseline; focused physical exams will be done thereafter. Physical exams and AE assessments can be done up to 3 days prior to dosing. 
4. Temperature, pulse, blood pressure, and respi[INVESTIGATOR_697], and pulse oxygen will be collected at baseline, and prior to each dose of study drug, and at EOT visit.  
5. Blood pressure will be measured every 5-10 minutes prior to each copanlisib dose (no more than 4 measurements) until there are 2 consecutive results ≤ 150/90 mmHg. If the blood pressure is 
≥ 150/90 mmHg, the investigator can consider a medical intervention (e.g. administration of 
dihydropyridine calcium channel blocker), or delaying the infusion of the study drug. Blood 
pressure will be measured at 0h (pre-dose), 30 min (mid-infusion), 60 min (end of infusion), and 
1h and 2h after the end of copanlisib infusion (±15 minute window for all BP measurements). 
6. CBC with differential includes: absolute neutrophil count, absolute lymphocyte count, absolute eosinophil count, and platelet count 
7. Chemistry panel includes: albumin, alkaline phosphatase, total bilirubin (direct bilirubin if total 
bili is > ULN), bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, LDH, magnesium, phosphorus, uric acid. 
Amylase and lipase to be down at screening and Day1 of every cycle. 
8. Fasting  glucose will be measured at 0h (pre-dose), and 1 hour (+/- 15min) after completion of 
copanlisib infusion and subsequently if clinically indicated at the discretion of the investigator. 
NOTE: if patient needs to take a low glycemic meal on infusion days, then glucose test should 
be taken prior to meal intake. Glucose measurements may be done by [CONTACT_345340][INVESTIGATOR_17276]. 
9. HbA1c to be tested at screening, on Day 1 of every three cycles (4, 7, 10, etc) starting at cycle 4, and at the EOT visit. 
10. HDL, LDL, triglycerides, total cholesterol; performed at Screen and Day 1 of every other cycle 
(starting at Cycle 2) 
11. If TSH is abnormal, T3 and FT4 will be assessed. 
12. Patients with positive tests for HBsAg or HIV are excluded from study.  Patients with positive test for anti-HCV antibody will be eligible if they are negative for HCV-RNA. These patients 
should perform HCV RNA test with PCR monthly through treatment and 6 months thereafter. 
If viral load becomes positive, patient should be withdrawn from the study. 
13. CMV PCR may be done up to 7 days prior to each Day 1 visit. CMV PCR should be done with 
J
1887/Version 7.0 / January 27, [ADDRESS_428913] is required.  
15. Bilirubin, hemoglobin, glucose, ketones, leukocytes, nitrite, pH, color, protein, RBC and WBC 
count, and specific gravity. Performed at baseline and Day 1 of every other cycle (starting at cycle2). 
16. Labs and research blood should be collected within a window of 3 days prior to dosing. Labs 
may be repeated prior to dosing if needed. 
17. MUGA scan or echocardiogram to measure LVEF; the method chosen at baseline must be the 
same throughout the whole study period (baseline and EOT); at EOT visit must be done if not 
previously done within 4 weeks. 
18. Radiologic evaluations and tumor measurements will be performed at baseline (within 28 days 
of dosing), prior to each odd cycle (up to 1 week prior), and at End of Treatment visit.  If patient 
comes off study for reasons other than disease progression, subject may have additional 
radiologic evaluations every [ADDRESS_428914]/abdomen/pelvis with contrast will be used, however, non-contrast CT chest and 
MRI abdomen/pelvis will be done for patients with contrast allergies. 
19. Biopsy to be collected at baseline and [ADDRESS_428915] dose of study drug (± 3 days, but before 
Cycle 2 Day 15 study drug).  An optional biopsy may be performed at the time of progression. 
Approximately 6 core biopsy specimens will be obtained at each biopsy. Tumor biopsy will not 
be performed if the tumor is not accessible or if biopsy is considered not in the patient’s best 
interest. 
20. Blood for PBMC and plasma will be collected at baseline/prior to first dose, [ADDRESS_428916] 4 weeks. 
22. Subjects who discontinue treatment will be followed (by [CONTACT_648], email or visit) every 12 weeks 
(± 2 weeks) after completion of EOT visit for up to 2 years or study closure to monitor overall 
survival.  Information on other cancer therapi[INVESTIGATOR_38207]. In 
addition, SAEs that occur within 100 days (+14 day reporting window) of the end of treatment 
or before initiation of a new antineoplastic treatment should also be followed and recorded. 
  
J1887/Version 7.0 / January 27, [ADDRESS_428917] 1.1 criteria ( Appendix E) 
 
9.[ADDRESS_428918], abdomen, and pelvis. Tumor imaging is strongly preferred 
to be acquired by [CONTACT_20420] (CT).  For the abdomen and pelvis, contrast-enhanced magnetic resonance imaging (MRI) may be used when CT with iodinated contrast is contraindicated, or when local practice mandates it. The same imaging technique regarding modality, ideally the same scanner, and the use of contrast should be used in a participant 
throughout the study to optimize the reproducibility of the assessment of existing and new 
tumor burden and improve the accuracy of the assessment of response or progression based on 
imaging. Body scans should be performed with breath-hold scanning techniques, if possible.  All baseline evaluations should be performed as closely as possible to the beginning of treatment and no more than [ADDRESS_428919] by [CONTACT_6492]-up imaging as outlined in the 
study calendar. All subsequent scans (post-treatment) will be compared to the same pretreatment scan that was used prior to initiating of study treatment.  
 All measurements should be taken and recorded in metric notation using a ruler or calipers.     The definition of measurability of lesions on CT scan is based on the assumption that CT slice thickness is [ADDRESS_428920] slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.   
 10. DATA REPORTING / REGULATORY REQUIREMENTS 
 Adverse event guidelines and instructions for AE reporting can be found in Section [ADDRESS_428921]. Nilofer Azad will hold the IND for this study. She will comply with all regulated reporting requirements to the FDA.   

J
1887/Version 7.0 / January 27, 2023 59 10.1 Da
ta Management 
 
All information will be collected on study-specific case report forms (CRFs) by [CONTACT_464]. 
These data will be reviewed for completeness and accuracy by [CONTACT_079] [INVESTIGATOR_12758].  
 
Protocol Chair 
The
 Protocol Chair and/or designee is responsible for performing the following tasks: 
 Coordinating, developi[INVESTIGATOR_007], submitting, and obtaining approval for the protocol as well as its subsequent amendments. 
 Assuring that all participating institutions are using the correct version of the protocol. 
 Taking responsibility for the overall conduct of the study at all participating institutions and for monitoring the progress of the study. 
 Reviewing and ensuring reporting of SAE 
 Reviewing data from all sites. 
 Coordinating Center (Johns Hopkins University) 
The
 Coordinating Center (or its representative) is responsible for performing the following 
tasks: 
 Ensuring that IRB approval has been obtained at each participating site prior to the first subject registration at that site, and maintaining copi[INVESTIGATOR_70695]. 
 Monitoring subject registration. 
 Collecting and compi[INVESTIGATOR_54924]. 
 Establishing procedures for documentation, reporting, and submitting of AE’s and SAE’s to the Protocol Chair, and all applicable parties. 
 Facilitating audits by [CONTACT_54965], or by [CONTACT_54966]. 
 
Participating Sites 
Par
ticipating sites are responsible for performing the following tasks: 
 Following the protocol as written, and the guidelines of Good Clinical Practice (GCP). 
 Submitting data to the Coordinating Center. 
 Consent subjects promptly and enroll eligible subjects in EDC. 
 Providing sufficient experienced clinical and administrative staff and adequate 
facilities and equipment to conduct a collaborative trial according to the protocol. 
 Maintaining regulatory binders on site and providing copi[INVESTIGATOR_345306]. 
 Collecting and submitting data according to the schedule specified by [CONTACT_760]. 
 
10.[ADDRESS_428922] accrual and the progress of the study. Meetings will include the protocol principal investigator, study coordinator(s), data manager(s), lead research nurses(s), sub-investigators (as appropriate), collaborators (as appropriate), and biostatisticians (as appropriate) involved with the conduct of the protocol. During these meetings matters related to the following will 
J
1887/Version 7.0 / January 27, 2023 60 be
 discussed: safety of protocol participants, validity and integrity of the data, enrollment rate 
relative to expectation, characteristics of participants, retention of participants, adherence to 
protocol (potential or real protocol violations), data completeness, and progress of data for objectives.  Monthly teleconferences will be scheduled to include the Coordinating Center and the clinical trial sites. During these meetings, the Coordinating Center and clinical trial sites shall discuss the following: study protocol updates, safety data, enrollment status, and progress of data for objectives.  
 
10.[ADDRESS_428923] accrual and the progress of the study. External monitoring will occur according to the following guidelines: 
 
Johns Hopkins SKCCC: The SKCCC Compliance Monitoring Program will provide external 
monitor
ing for JHU-affiliated sites in accordance with SKCCC DSMP (Version 6.0, 
02/21/2019). The SMC Subcommittee will determine the level of patient safety risk and level/frequency of monitoring.  Participating site(s): The protocol will be monitored at each participating site by a member of 
the
 Johns Hopkins study team regulatory staff. A report of the reviews will be submitted to the 
Johns Hopkins principal investigator [INVESTIGATOR_270203]. 
 
11. STATISTICAL CONSIDERATIONS 
 
11.[ADDRESS_428924] 3+[ADDRESS_428925] cycle for each patient.  An initial cohort of 3 patients will be enrolled. If 0-1/[ADDRESS_428926] a DLT then 3 additional patients will be enrolled at the same dose level.  If 2-3/3 DLTs are observed, then the dose will be considered too toxic 
and the next lower dose level will be enrolled.  The RP2D is the dose at which  1/[ADDRESS_428927] a DLT (i.e. if 0/[ADDRESS_428928] feasible dose to establish the RP2D).  During Phase II 42 patients will be recruited: 21 patients with colorectal cancer with PIK3CA mutation (cohort A) and 21 with WT PIK3CA with known lack of sensitivity to immune checkpoint inhibitor therapy (cohort B). ORR (CR+PR) at 6 months the primary endpoint and will be evaluated separately in each cohort. Enrollment will be carried out in 2 stages so that the study can terminate early if the combination of copanlisib and nivolumab is not sufficiently effective. A design similar to Simon’s minimax design with relaxed futility stoppi[INVESTIGATOR_345307] 5% or less.
30-[ADDRESS_428929] 12 patients, the study will be terminated for futility. Otherwise, 9 additional patients will be accrued for a 
J
1887/Version 7.0 / January 27, 2023 61 total 
of 21 treated subjects. Patients who withdraw consent before disease re-evaluation will 
not be considered evaluable for response and may be replaced. Patients who come off of study 
prior to disease re-evaluation with imaging due to clinical deterioration will be considered 
evaluable for response and will be coded as progressing. If [ADDRESS_428930] a 
response, then the trial will be considered a success for that cohort.  If the true response rate is 
20% (alternative hypothesis rate), then the probability of a declaring the treatment a success is 0.80 (power).  If the true response rate is 5% (null hypothesis rate), then the probability of declaring the treatment a success is 0.08 (type I error). 
 
11.[ADDRESS_428931] (e.g. cohort).  The descriptive summary including demographics and baseline variables will include counts and percentages for categorical variables and means, medians, standard deviations, and quartiles for continuous variables.  ORR at 6 months, the primary outcome for Phase II, will be summarized using counts and percentages.  Logistic regression will be used to compare the ORR between the two cohorts as well as to identify risk factors associated with ORR.  Other binary outcomes (e.g. disease control at 6 months (SD+PR+CR) and immunologic response) will be analyzed using the same methods.  Time to event outcomes include overall survival (OS) and progression free survival (PFS).  Overall survival is defined as the time from the first dose until death.  Individuals without an event will be censored at the date of last contact.  Progression free survival is defined as the time from the first dose until progression or death.  Individuals who die will be counted as having progressed.  Individuals without an event will be censored at the date of the last evaluation for progression.   Kaplan-Meier curves will be use to graphically summarize the survival function and to estimate the median time to event and the proportion event-free at key intervals (e.g. 6 months) along with 95% confidence intervals.  Cox proportional hazards models will be used to compare Cohorts A and B and to identify risk factors associated with OS and PFS.  Graphical techniques (e.g. log-log plots) and formal statistical testing (e.g. Schoenfield tests) will be used to assess the proportional hazards assumption.  If necessary, alternate models (e.g. incorporating a time variable) will be considered.  Safety will be monitored continuously throughout the study, including the phase II component.  Weekly team meetings and a minimum of monthly investigator calls will be conducted to review ongoing and resolved toxicity.  Exploratory correlative outcomes are an important part of the study.  Paired tumor biopsies will be collected prior to and after initial treatment.  Continuous measurements (e.g. density of immune cells, peripheral blood cytokine expression, percentage of CD8+ Tcells expressing >= 2 inhibitory receptors, and CD8+ cytokine expression) will be evaluated graphically (e.g. histograms) and numerically (e.g. means, medians) to determine whether or not a transformation (e.g. log) is appropriate.   Once the appropriate scale has been determined, graphical techniques, including but not limited to boxplots spaghetti plots, will be used to summarize the values at each time point and the change from pre-to post- treatment.   The 
J
1887/Version 7.0 / January 27, 2023 62 me
ans and 95% confidence intervals of each of these quantities will be estimated.  A variety 
of tools including Wilcoxon rank-sum tests and linear regression, with the change as the 
outcome variable, will be used to determine whether there is a significant change within each group, whether the changes differ between cohorts, and the association between immunologic parameters and response status (CR/PR or SD vs PD).  Linear mixed effects models, which account for the correlation between repeated measurements from an individual and allow the inclusion of additional time points, will also be explored.   The baseline and change scores will also be considered as potential risk factors for ORR, OS, and PFS using the analysis techniques described above.  Serial samples of PBMC and plasma will be evaluated in a similar manner with greater emphasis on the longitudinal modeling due to the greater abundance of repeat measurements.  Genomic sequencing library construction, whole genome/exome sequencing, whole 
transcriptome sequencing, microbial sequencing, neoepi[INVESTIGATOR_178518], mutation burden, 
and bioinformatic analysis may be performed either at an on-campus laboratory or at an off-
campus sequencing service. All the samples will be de-identified before sending to any laboratory for sequencing.  The FASTQ files, BAM files and VCF files will be generated and analyzed. Other sequencing assays may be performed on a subset of samples according to 
specific requirements of collaboration projects. Genomic sequencing data will be stored and 
computations conducted using a JH IT managed subscription of Azure. 
 
11.3 Safety Analyses 
 
AE data will be listed individually and incidence of AEs will be summarized by [CONTACT_345341] a system organ class for Phase I and Phase II (overall and within each cohort). When calculating the incidence of AEs, each AE will be counted only once for a given subject.  In analyses of grade and causality, if the same AE occurs on multiple occasions, the highest grade and strongest relationship to study drug will be assumed.  If [ADDRESS_428932] AE, will be analyzed for all AEs and by [CONTACT_345342].  In addition, the event rates (which incorporate multiple AEs of the same type) will be analyzed using Negative Binomial regression.  Changes in vital signs, hematology and clinical chemistry parameters from baseline to the end of the study will be examined.  Toxicity will be tabulated by [CONTACT_16624]. Toxicities will be characterized according to the CTCAE version 5.0.  Treatment-emergent changes from normal to abnormal values in key laboratory parameters will be identified.  Incidence and rate evaluations will follow the methods described for AEs.  
11.4 Safety Monitoring The proportion of treated subjects with unacceptable toxicity will be monitored using a 
Bayesian stoppi[INVESTIGATOR_345308] (Cohort A: colorectal cancer with PIK3CA mutation and Cohort B: WT PIK3CA with known lack of sensitivity to immune checkpoint 
inhibitor therapy) separately during Phase II. A (1.5, 5.5), representing a toxicity rate of 21%, 
the slightly higher than the expected toxicity rate, was used in the development of our 
guidelines.  These guidelines will recommend that recruitment be halted and the trial be 
J
1887/Version 7.0 / January 27, 2023 63 re
assessed if the posterior probability that the unacceptable toxicity rate exceeds the maximum 
allowable rate (33%) is greater than 0.55.  Once the initial 6 patients are recruited, toxicity will 
be monitored continuously.  Table 11  summarizes the stoppi[INVESTIGATOR_345309].  
Table 11:   The number of toxicities needed to trigger stoppi[INVESTIGATOR_345310]. 
Number of Subjects 
Per Cohort  Number of toxicities 
needed to trigger 
re-evaluation 
6-8 4 
9-11 5 
12-14 6 
15-17 7 
18-20 8 
21 9 
 
The
 probability of triggering the stoppi[INVESTIGATOR_70685] a range of possible true 
toxicity rates using simulations with 10,000 replicates ( Table 12 ).  The probability of stoppi[INVESTIGATOR_345311]-evaluate was 9.5% if the true proportion with an unacceptable toxicity was 20%, the expected level.  In comparison, the probability of stoppi[INVESTIGATOR_30492] 54% and 70% if the true proportion with an unacceptable toxicity was 35% or 40%, i.e. above the 33% threshold.    Table 12:  Probability of triggering a re-evaluation based upon the proportion with an 
unacceptable toxicity for a range of true toxicity probabilities.  
True probability of 
unacceptable toxicity Probability of 
triggering 
stoppi[INVESTIGATOR_007]  g
uidelines  
5% <
 0.1%  
10% 0.8% 
15% 3.1%  
20% 9.5%  
25% 21% 
30% 37% 
35% 54% 
40% 70% 
  
J
1887/Version 7.0 / January 27, 2023 64 12. REF
ERENCES 
 
1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23: 515-548. 2. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by [CONTACT_13223] 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98: [ZIP_CODE]-[ZIP_CODE]. 3. Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20: 337-347. 4. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173: 945-954. 5. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574: 37-41. 6. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229: 114-125. 7. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-[ADDRESS_428933] mechanisms. Mol Cell Biol. 2005;25: 9543-9553. 8. Francisco LM, Sage PT, Sharpe AH. The PD-[ADDRESS_428934] in tolerance and autoimmunity. Immunol Rev. 2010;236: 219-242. 9. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine. 2012;366: 2455-2465. 10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipi[INVESTIGATOR_15173]. New England Journal of Medicine. 2010;363: 711-723. 11. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England Journal of Medicine. 2015;373: 1803-1813. 12. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. The New England Journal of Medicine. 2016;375: 1823-1833. 13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine. 2012;366: 2443-2454. 14. Wee S, Wiederschain D, Maira S-MM, et al. PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. 2008;105: [ZIP_CODE]-[ZIP_CODE]. 15. Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer discovery. 2016;6: 202-216. 16. George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46: 197-204. 17. Sai J, Owens P, Novitskiy SV, et al. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Anti-tumor Immunity and Anti-PD1 Responses. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016. 18. Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547: 413-418. 19. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502: 333-339. 20. Kim E, Ilic N, Shrestha Y, et al. Systematic Functional Interrogation of Rare Cancer Variants 
J
1887/Version 7.0 / January 27, 2023 65 I
dentifies Oncogenic Alleles. Cancer discovery. 2016;6: 714-726. 
21. Network C. Comprehensive molecular characterization of human colon and rectal cancer. 
Nature. 2012;487: 330-337. 22. Tsujikawa T, Kumar S, Borkar RN, et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell reports. 2017;19: 203-217. 23. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by [CONTACT_25505]-cell RNA-seq. Science. 2016;352: 189-196. 24. Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by [CONTACT_4002]-1-targeted therapi[INVESTIGATOR_345312]28-dependent. Science ([LOCATION_001], N.Y.). 2017;355: 1423-1427. 25. Stubbington MJT, Lonnberg T, Proserpio V, et al. T cell fate and clonality inference from single-cell transcriptomes. Nat Methods. 2016;13: 329-332. 26. Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by [CONTACT_345343]. Nat Biotechnol. 2014;32: 381-386. 27. Wagner A, Regev A, Yosef N. Revealing the vectors of cellular identity with single-cell genomics. Nat Biotechnol. 2016;34: 1145-1160. 28. DeTomaso D, Yosef N. FastProject: a tool for low-dimensional analysis of single-cell RNA-Seq data. BMC Bioinformatics. 2016;17: 315. 29. Farren MR, Mace TA, Geyer S, et al. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22: 2565-2574. 30. Le et al. J Clin Oncol 33, 2015 (suppl; abstr LBA100).  31. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber  BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi  TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. 
  
J
1887/Version 7.0 / January 27, 2023 66 AP
PENDIX A: Performance Status Criteria 
 
ECOG Performance Status Scale Karnofsky Performance Scale 
Gr
ade De
scriptions  Per
cent De
scription  
0 No
rmal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction. 100 Normal, no complaints, no evidence 
of
 disease.  
90 Ab
le to carry on normal activity; 
minor
 signs or symptoms of disease.  
1 S
ymptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Car
es for self, unable to carry on 
normal activity or to do active work. 
2 I
n bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. [ADDRESS_428935] of his/her 
ne
eds. 
50 Req
uires considerable assistance and 
fr
equent medical care.  
3 I
n bed >50% of the time.  Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
a
ssistance.  
30 Seve
rely disabled, hospi[INVESTIGATOR_345313].  Death not imminent.  
4 100%
 bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospi[INVESTIGATOR_374]. 
De
ath not imminent.  
10 Mor
ibund, fatal processes 
pr
ogressing rapi[INVESTIGATOR_375].  
5 De
ad. 0 De
ad. 
          
  
J
1887/Version 7.0 / January 27, 2023 67 AP
PENDIX B: Contraceptive Guidance and Pregnancy Testing 
 
Woman of Childbearing Potential (WOCBP) 
A 
woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below)  Women in the following categories are not considered WOCBP: 
 Premenarchal 
 Premenopausal female with 1 of the following: 
- Documented hysterectomy 
- Documented bilateral salpi[INVESTIGATOR_1656] 
- Documented bilateral oophorectomy 
Note:  Documentation can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview. 
 Postmenopausal female ○ Defined as no menses for 12 months without an alternative medical cause.  ○ Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
 Contraception Requirements 
M
ale Participants:  
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to one of the following for the duration of the study and for [ADDRESS_428936] dose of study drug:  
 Agree to be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
 Agree to use a male condom plus partner use of a contraceptive method with a failure rate 
of <1% per year as described in Table 8 when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant. 
○ Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each epi[INVESTIGATOR_117492]. 
Note: male participants will be considered to be of non-reproductive potential if they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition). 
 
F
emale Participants:  
F
emale participants of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in Table [ADDRESS_428937] dose of study drug:   
J
1887/Version 7.0 / January 27, 2023 68 Table 13 - Highly E
ffective Contraception Methods 
 
Hi
ghly Effective Contraceptive Methods That Are User Dependent a  
Failu
re rate of < 1% per year when used consistently and cor
rectly.  
● C
ombined (estrogen- and progestogen- containing ) hormonal contraception b, 
c 
○ O
ral  
○ Intravaginal  
○ Transdermal  
○ Injectable 
● Prog
estogen-only hormonal contraception b
, c 
○ O
ral  
○ Injectable  
Hi
ghly Effective Methods That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
● Prog
estogen- only contraceptive implant b, c  
● I
ntrauterine hormone-releasing system (IUS) b  
● I
ntrauterine device (IUD) 
● Bilateral tubal occlusion 
 
● V
asectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed.  If not, an additional 
hig
hly effective method of contraception should be used.  
● Sex
ual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
pref
erred and usual lifestyle of the participant.)  
N
otes:  
Use should be consistent with local regulations regarding the use of contraceptive methods for 
participants of clinical studies.  
 
a) T
ypi[INVESTIGATOR_122955]-use failure rates (i.e. when used consistently and 
correctly).  
b) If hormonal contraception efficacy is potentially decreased due to interaction with study treatment, 
condoms must be used in addition to the hormonal contraception during the treatment period and for at 
least [ADDRESS_428938] dose of study treatment. 
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
accep
table hormonal contraceptives are lim it
ed to those which inhibit ovulation.  
 
Pre
gnancy Testing 
WOCB
P should only be included after a negative highly sensitive urine or serum pregnancy test.  
Following initiation of treatment, pregnancy testing will be performed whenever an expected menstrual cycle is missed or when pregnancy is otherwise suspected, after the last dose of study treatment, and as required locally.   
  
J
1887/Version 7.0 / January 27, 2023 69 AP
PENDIX C: Management Algorithms 
 
These general guidelines constitute guidance to the Investigator and may be supplemented by [CONTACT_345344]. The guidance applies to all immuno-oncology (I-O) agents and regimens.  A general principle is that differential diagnoses should be diligently evaluated according to standard medical practice. Non-inflammatory etiologies should be considered and appropriately treated.  Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. The oral equivalent of the recommended IV doses may be considered for ambulatory subjects with low-grade toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.  Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic procedure, is recommended . 
 The frequency and severity of the related adverse events covered by [CONTACT_70744]-oncology agent or regimen being used.  
          
J
1887/Version 7.0 / January 27, 2023 70  

J
1887/Version 7.0 / January 27, 2023 71  
 

J
1887/Version 7.0 / January 27, 2023 72  

J
1887/Version 7.0 / January 27, 2023 73  

J
1887/Version 7.0 / January 27, 2023 74  

J
1887/Version 7.0 / January 27, 2023 75  

J
1887/Version 7.0 / January 27, 2023 76   
  

 
J
1887/Version 7.0 / January 27, 2023 77 AP
PENDIX D: Average Glycemic Index of Common Foods  
 
The average Glycemic Index of common foods derived from multiple studies by [CONTACT_345345] a low-glycemic index if the glucose reference index is ≤ 55. High-Glycemic Index foods have a glucose reference index >55. The summary table below contains glucose reference for common foods.  
 
   

 
J
1887/Version 7.0 / January 27, 2023 78 AP
PENDIX E: Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_428939] is the preferred imaging technique in this study.   
Disease Parameters 
 Measurable disease:  Measurable lesions are defined as those that can be accurately measured in 
a
t least one dimension (longest diameter to be recorded) as >[ADDRESS_428940] x-ray, as >[ADDRESS_428941] scan, or >[ADDRESS_428942] be 
re
corded in millimeters (or decimal fractions of centimeters). 
 
No
te:  Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable unless there is evidence of progression in the irradiated site. Malignant 
l
ymph nodes.  To be considered pathologically enlarged and measurable, a lymph node must 
be
 >[ADDRESS_428943] scan (CT scan slice thickness recommended to 
be
 no greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured 
and followed. 
 
Non-measurable disease:  All other lesions (or sites of disease), including small lesions (longest 
dia
meter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by [CONTACT_462]), are considered as non-measurable.  
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by [CONTACT_108], simple cysts.  ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same subject, these are preferred for selection as target lesions. 
 
Target lesions:  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, 
representative of all involved organs, should be identified as target lesions  and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected.  A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.  Non-target lesions:  All other lesions (or sites of disease) including any measurable lesions over 
a
nd above the 5 target lesions should be identified as non-target lesions and should also be 
 
J
1887/Version 7.0 / January 27, 2023 79 re
corded at baseline.  Measurements of these lesions are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up.  
 Evaluation of Target Lesions  Complete Response (CR): Disappearance of all target lesions.  Any pathological lymph nodes 
(w
hether target or non-target) must have reduction in short axis to <10 mm. 
 Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking 
a
s reference the baseline sum diameters. 
 Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, 
tak
ing as reference the smallest sum on study (this includes the baseline sum if that is the smallest 
on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also considered progressions).  Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qua
lify for PD, taking as reference the smallest sum diameters while on study. 
 Evaluation of Non-Target Lesions  Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
ma
rker level.  All lymph nodes must be non-pathological in size (<10 mm short axis). 
 Note:  If tumor markers are initially above the upper normal limit, they must normalize for a subject to be considered in complete clinical response.  Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
ma
rker level above the normal limits. 
 Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression  
of
 existing non-target lesions.  Unequivocal progression  should not normally trump target lesion 
status.  It must be representative of overall disease status change, not a single lesion increase.      Although a clear progression of “non-target” lesions only is exceptional, the opi[INVESTIGATOR_36408], and the progression status should be confirmed at a later time by [CONTACT_463] (or Principal Investigator).  Evaluation of Best Overall Response  The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  The subject's best response assignment will depend on the achievement of both measurement and confirmation criteria.   For Subjects with Measurable Disease (i.e., Target Disease) 
 
 
J
1887/Version 7.0 / January 27, [ADDRESS_428944]
 Overall 
Response when 
Confirmation is 
Required* 
CR CR No CR >4 w
ks. 
Conf
irmation**  
CR No
n-CR/Non-
PD No PR 
>4 w
ks. 
Conf
irmation** CR No
t evaluated  No PR 
PR No
n-CR/Non-
PD/not 
e
valuated  No PR 
SD No
n-CR/Non-
PD/not 
e
valuated  No SD Do
cumented at least 
once >4 wks. from 
ba
seline**  
PD Any Ye
s or 
No PD 
no pr
ior SD, PR or CR  Any PD*** Ye
s or 
No PD 
Any Any Ye
s PD 
* See
 RECIST 1.1 manuscript for further details on what is evidence of 
a new lesion. 
** Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, unequivocal progression in non-target 
lesions may be accepted as disease progression. 
 
Note: Subjects with a global deterioration of health status requiring 
disc
ontinuation of treatment without objective evidence of disease 
progression at that time should be reported as “ symptomatic 
deterioration.”  Every effort should be made to document the 
obje
ctive progression even after discontinuation of treatment.  
 
R
eference 
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. 
Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. New 
response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).  Eur J Cancer. 2009 
Jan;45(2):228-47.  
 
  
 
J1887/Version 7.0 / January 27, 2023 81 APPENDIX F: Serious Adverse Event (SAE) Reporting Form 
 
Serious Adverse Event Reporting Form 
 
 
Protocol Title: 
 
 A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody 
nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal 
cancer  
Protocol #: Principal Investigator: 
 [INVESTIGATOR_377]: 
 Date: 
 
Report Type: 
Initial    
Follow-up 
Final Follow-up 
Death 
Addendum to: 
 Serious Criteria / Outcome 
(check all that apply): 
Death    
Life-threatening 
 Hospi[INVESTIGATOR_345314] / Birth Defect 
 Other Important Medical Event 
 New Cancer 
 AE associated with Overdose  Hospi[INVESTIGATOR_345315]:  
  Hospi[INVESTIGATOR_345316]:   Date Event Discovered: 
 
 
Section A: Subject Information 
Subject ID: 
 Age (years): Gender: 
Male  Female  
Section B: Event and Study Drug Information 
Event diagnosis or 
symptoms:   Copanlisib Nivolumab  
Dose and Route:   240mg IV 
Dx for Use (indication):    
Date of First Dose:    
Date of Last Dose  
Prior to Event:    
# of Total Doses:    
Action Taken  
w/ study drug  None 
Interrupted 
Discontinued 
Delayed  None 
Interrupted 
Discontinued 
Delayed  Event Grade: 
 
 Event Abated after use 
stopped/ reduced?  Yes    No    N/A Yes    No    N/A 
Event Reappeared After 
Reintroduction?  Yes    No    N/A Yes    No    N/A 
Event Onset Date: 
 Event End Date: 
 
Relationship to:  Copanlisib Nivolumab Underlying Disease 
Unrelated     

 
J
1887/Version 7.0 / January 27, 2023 82 Rela
ted    
Sec
tion C: Brief Description of the Event 
 
               
 
Sec
tion D: Relevant Tests/Laboratory Data 
 
Sec
tion E: Relevant Medical History 
  
Sec
tion F: Concomitant Drug (Not related to SAE) 
Na
me of the Drug Start Date Stop Date Route Dose Frequency 
      
      
      
      
      
      
Sec
tion G: Comments 
Additional Do
cuments Attached (labs, scans, notes, etc):  Plea
se specify, including dates  
 
 